IL-2	B-DNA
gene	I-DNA
expression	O
and	O
NF-kappa	B-protein
B	I-protein
activation	O
through	O
CD28	B-protein
requires	O
reactive	O
oxygen	O
production	O
by	O
5-lipoxygenase	B-protein
.	O

Activation	O
of	O
the	O
CD28	B-protein
surface	I-protein
receptor	I-protein
provides	O
a	O
major	O
costimulatory	O
signal	O
for	O
T	O
cell	O
activation	O
resulting	O
in	O
enhanced	O
production	O
of	O
interleukin-2	B-protein
(	O
IL-2	B-protein
)	O
and	O
cell	O
proliferation	O
.	O

In	O
primary	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
we	O
show	O
that	O
CD28	B-protein
ligation	O
leads	O
to	O
the	O
rapid	O
intracellular	O
formation	O
of	O
reactive	O
oxygen	O
intermediates	O
(	O
ROIs	O
)	O
which	O
are	O
required	O
for	O
CD28	B-protein
-mediated	O
activation	O
of	O
the	O
NF-kappa	B-protein
B	I-protein
/	O
CD28-responsive	B-protein
complex	I-protein
and	O
IL-2	B-protein
expression	O
.	O

Delineation	O
of	O
the	O
CD28	B-protein
signaling	O
cascade	O
was	O
found	O
to	O
involve	O
protein	B-protein
tyrosine	I-protein
kinase	I-protein
activity	O
,	O
followed	O
by	O
the	O
activation	O
of	O
phospholipase	B-protein
A2	I-protein
and	O
5-lipoxygenase	B-protein
.	O

Our	O
data	O
suggest	O
that	O
lipoxygenase	B-protein
metabolites	I-protein
activate	O
ROI	O
formation	O
which	O
then	O
induce	O
IL-2	B-protein
expression	O
via	O
NF-kappa	B-protein
B	I-protein
activation	O
.	O

These	O
findings	O
should	O
be	O
useful	O
for	O
therapeutic	O
strategies	O
and	O
the	O
development	O
of	O
immunosuppressants	O
targeting	O
the	O
CD28	B-protein
costimulatory	O
pathway	O
.	O

The	NULL
EMBO	NULL
Journal	NULL
vol.14	NULL
no.15	NULL
pp.3731-3740	NULL
,	NULL
1995	NULL
IL-2	NULL
gene	NULL
expression	NULL
and	NULL
NF-xB	NULL
activation	NULL
through	NULL
CD28	NULL
requires	NULL
reactive	NULL
oxygen	NULL
production	NULL
by	NULL
5-lipoxygenase	NULL
Marek	NULL
Los	NULL
,	NULL
Heike	NULL
Schenk	NULL
,	NULL
Klaus	NULL
Hexel*	NULL
,	NULL
Patrick	NULL
A.Baeuerle	NULL
'	NULL
,	NULL
Wulf	NULL
Droge*	NULL
and	NULL
Klaus	NULL
Schulze-Osthoff'**	NULL
'Institute	NULL
of	NULL
Biochemistry	NULL
,	NULL
Albert-Ludwigs-University	NULL
,	NULL
D-79104	NULL
Freiburg	NULL
,	NULL
and	NULL
Division	NULL
of	NULL
Immunochemistry	NULL
,	NULL
German	NULL
Cancer	NULL
Research	NULL
Center	NULL
,	NULL
D-69120	NULL
Heidelberg	NULL
,	NULL
Germany	NULL
*Corresponding	NULL
author	NULL
Communicated	NULL
by	NULL
P.A.Baeuerle	NULL
Activation	NULL
of	NULL
the	NULL
CD28	NULL
surface	NULL
receptor	NULL
provides	NULL
a	NULL
major	NULL
costimulatory	NULL
signal	NULL
for	NULL
Tcell	NULL
activation	NULL
resulting	NULL
in	NULL
enhanced	NULL
production	NULL
of	NULL
interleukin-2	NULL
(	NULL
IL-2	NULL
)	NULL
and	NULL
cell	NULL
proliferation	NULL
.	NULL

In	NULL
primary	NULL
T	NULL
lymphocytes	NULL
we	NULL
show	NULL
that	NULL
CD28	NULL
ligation	NULL
leads	NULL
to	NULL
the	NULL
rapid	NULL
intracellular	NULL
formation	NULL
of	NULL
reactive	NULL
oxygen	NULL
intermediates	NULL
(	NULL
ROIs	NULL
)	NULL
which	NULL
are	NULL
required	NULL
for	NULL
CD28-mediated	NULL
activation	NULL
of	NULL
the	NULL
NF-xB/CD28-responsive	NULL
complex	NULL
and	NULL
IL-2	NULL
expression	NULL
.	NULL

Delineation	NULL
of	NULL
the	NULL
CD28	NULL
signaling	NULL
cascade	NULL
was	NULL
found	NULL
to	NULL
involve	NULL
protein	NULL
tyrosine	NULL
kinase	NULL
activity	NULL
,	NULL
followed	NULL
by	NULL
the	NULL
activation	NULL
of	NULL
phospholipase	NULL
A	NULL
;	NULL
and	NULL
S-lipoxygenase	NULL
.	NULL

Our	NULL
data	NULL
suggest	NULL
that	NULL
lipoxygenase	NULL
metabolites	NULL
activate	NULL
ROI	NULL
formation	NULL
which	NULL
then	NULL
induce	NULL
IL-2	NULL
expression	NULL
via	NULL
NF-	NULL
«	NULL
B	NULL
activation	NULL
.	NULL

These	NULL
findings	NULL
should	NULL
be	NULL
useful	NULL
for	NULL
therapeutic	NULL
strategies	NULL
and	NULL
the	NULL
development	NULL
of	NULL
immunosuppressants	NULL
targeting	NULL
the	NULL
CD28	NULL
costimulatory	NULL
pathway	NULL
.	NULL

Keywords	NULL
:	NULL
CD28/costimulation/IL-2/NF-	NULL
«	NULL
xB/ROI	NULL
Introduction	NULL
T	NULL
lymphocytes	NULL
require	NULL
distinct	NULL
signals	NULL
from	NULL
antigen-presenting	NULL
cells	NULL
for	NULL
activation	NULL
(	NULL
reviewed	NULL
by	NULL
Mueller	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Jenkins	NULL
and	NULL
Johnson	NULL
,	NULL
1993	NULL
;	NULL
Crabtree	NULL
and	NULL
Clipstone	NULL
,	NULL
1994	NULL
)	NULL
.	NULL

An	NULL
antigen-specific	NULL
stimulus	NULL
is	NULL
delivered	NULL
through	NULL
the	NULL
T	NULL
cell	NULL
receptor	NULL
(	NULL
TCR	NULL
)	NULL
following	NULL
the	NULL
binding	NULL
of	NULL
TCR	NULL
to	NULL
antigenic	NULL
peptides	NULL
presented	NULL
by	NULL
MHC	NULL
molecules	NULL
.	NULL

However	NULL
,	NULL
while	NULL
engagement	NULL
of	NULL
the	NULL
TCR	NULL
triggers	NULL
the	NULL
initial	NULL
steps	NULL
of	NULL
T	NULL
cell	NULL
activation	NULL
,	NULL
TCR	NULL
stimulation	NULL
is	NULL
not	NULL
sufficient	NULL
to	NULL
ensure	NULL
a	NULL
full	NULL
immune	NULL
response	NULL
.	NULL

Complete	NULL
T	NULL
cell	NULL
activation	NULL
requires	NULL
a	NULL
second	NULL
costimulatory	NULL
signal	NULL
,	NULL
since	NULL
TCR	NULL
signaling	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
an	NULL
accessory	NULL
cell-derived	NULL
costimulus	NULL
leads	NULL
to	NULL
anergy	NULL
and	NULL
a	NULL
long-lasting	NULL
state	NULL
of	NULL
unresponsiveness	NULL
to	NULL
antigenic	NULL
stimulation	NULL
(	NULL
Harding	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
;	NULL
Crabtree	NULL
and	NULL
Clipstone	NULL
,	NULL
1994	NULL
)	NULL
.	NULL

TCR	NULL
stimulation	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
costimulatory	NULL
signals	NULL
may	NULL
also	NULL
lead	NULL
to	NULL
cell	NULL
death	NULL
in	NULL
previously	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
Punt	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

An	NULL
important	NULL
costimulus	NULL
which	NULL
can	NULL
reverse	NULL
induction	NULL
of	NULL
anergy	NULL
and	NULL
programmed	NULL
cell	NULL
death	NULL
is	NULL
the	NULL
CD28	NULL
surface	NULL
receptor	NULL
that	NULL
is	NULL
expressed	NULL
on	NULL
the	NULL
majority	NULL
of	NULL
thymocytes	NULL
and	NULL
peripheral	NULL
T	NULL
lymphocytes	NULL
(	NULL
reviewed	NULL
by	NULL
Linsley	NULL
and	NULL
Ledbetter	NULL
,	NULL
1993	NULL
;	NULL
June	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

CD28	NULL
is	NULL
a	NULL
homodimeric	NULL
molecule	NULL
composed	NULL
of	NULL
two	NULL
44	NULL
kDa	NULL
subunits	NULL
.	NULL

Its	NULL
predicted	NULL
©	NULL
Oxford	NULL
University	NULL
Press	NULL
sequence	NULL
is	NULL
that	NULL
of	NULL
a	NULL
receptor	NULL
of	NULL
the	NULL
Ig	NULL
superfamily	NULL
with	NULL
a	NULL
single	NULL
Vy-like	NULL
domain	NULL
in	NULL
the	NULL
extracellular	NULL
part	NULL
,	NULL
a	NULL
transmembrane	NULL
region	NULL
and	NULL
a	NULL
short	NULL
intracellular	NULL
domain	NULL
(	NULL
Aruffo	NULL
and	NULL
Seed	NULL
,	NULL
1987	NULL
)	NULL
.	NULL

The	NULL
counter-receptor	NULL
for	NULL
CD28	NULL
is	NULL
B7	NULL
which	NULL
is	NULL
expressed	NULL
on	NULL
activated	NULL
B	NULL
cells	NULL
,	NULL
dendritic	NULL
cells	NULL
and	NULL
macrophages	NULL
(	NULL
reviewed	NULL
by	NULL
June	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

At	NULL
least	NULL
two	NULL
forms	NULL
of	NULL
B7	NULL
(	NULL
B7-1/CD80	NULL
and	NULL
B7-2/B70	NULL
)	NULL
exist	NULL
and	NULL
both	NULL
are	NULL
members	NULL
of	NULL
the	NULL
Ig	NULL
superfamily	NULL
.	NULL

B7	NULL
also	NULL
binds	NULL
to	NULL
CTLA-4	NULL
,	NULL
a	NULL
receptor	NULL
that	NULL
is	NULL
structurally	NULL
related	NULL
to	NULL
CD28	NULL
and	NULL
expressed	NULL
in	NULL
low	NULL
copy	NULL
number	NULL
following	NULL
T	NULL
cell	NULL
activation	NULL
(	NULL
Linsley	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

Triggering	NULL
of	NULL
the	NULL
CD28	NULL
receptor	NULL
in	NULL
conjunction	NULL
with	NULL
stimulation	NULL
of	NULL
the	NULL
TCR-CD3	NULL
complex	NULL
strongly	NULL
enhances	NULL
T	NULL
cell	NULL
proliferation	NULL
and	NULL
T	NULL
cell	NULL
cytotoxic	NULL
activity	NULL
(	NULL
reviewed	NULL
by	NULL
June	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

A	NULL
major	NULL
effect	NULL
of	NULL
the	NULL
CD28	NULL
costimulus	NULL
consists	NULL
of	NULL
the	NULL
enhanced	NULL
production	NULL
of	NULL
cyto-kines	NULL
,	NULL
such	NULL
as	NULL
IL-2	NULL
,	NULL
IFN-y	NULL
,	NULL
GM-CSF	NULL
,	NULL
TNF	NULL
and	NULL
others	NULL
,	NULL
which	NULL
are	NULL
upregulated	NULL
by	NULL
both	NULL
transcriptional	NULL
and	NULL
post-transcriptional	NULL
processes	NULL
(	NULL
Martin	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
;	NULL
Guba	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Thompson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Cerdan	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
,	NULL
1992	NULL
)	NULL
.	NULL

It	NULL
has	NULL
been	NULL
observed	NULL
that	NULL
CD28	NULL
stimulation	NULL
leads	NULL
to	NULL
the	NULL
coordinate	NULL
stabilization	NULL
of	NULL
the	NULL
mRNAs	NULL
for	NULL
these	NULL
cytokines	NULL
(	NULL
Lindsten	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
these	NULL
post-transcriptional	NULL
events	NULL
,	NULL
IL-2	NULL
mRNA	NULL
levels	NULL
are	NULL
increased	NULL
due	NULL
to	NULL
enhanced	NULL
transcriptional	NULL
activity	NULL
.	NULL

Studies	NULL
on	NULL
the	NULL
IL-2	NULL
promoter	NULL
have	NULL
identified	NULL
a	NULL
CD28-responsive	NULL
element	NULL
(	NULL
CD28RE	NULL
)	NULL
with	NULL
enhancer	NULL
activity	NULL
(	NULL
Fraser	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
;	NULL
Verweij	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

The	NULL
nucleotide	NULL
sequence	NULL
of	NULL
CD28RE	NULL
is	NULL
structurally	NULL
related	NULL
to	NULL
the	NULL
classical	NULL
xB	NULL
consensus	NULL
sequence	NULL
and	NULL
was	NULL
found	NULL
to	NULL
bind	NULL
a	NULL
CD28-responsive	NULL
complex	NULL
(	NULL
CD28RC	NULL
)	NULL
consisting	NULL
of	NULL
protein	NULL
subunits	NULL
of	NULL
the	NULL
NF-xB	NULL
family	NULL
(	NULL
Verweij	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
;	NULL
Costello	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

In	NULL
accordance	NULL
,	NULL
stimulation	NULL
of	NULL
CD28	NULL
in	NULL
lymphocytes	NULL
pretreated	NULL
with	NULL
anti-CD3	NULL
or	NULL
phorbolesters	NULL
results	NULL
in	NULL
increased	NULL
nuclear	NULL
amounts	NULL
of	NULL
the	NULL
NF-xB	NULL
proteins	NULL
p50	NULL
,	NULL
p65	NULL
and	NULL
c-Rel	NULL
(	NULL
Ghosh	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

In	NULL
Jurkat	NULL
T	NULL
cells	NULL
,	NULL
it	NULL
has	NULL
been	NULL
further	NULL
observed	NULL
that	NULL
CD28	NULL
activates	NULL
JNK	NULL
,	NULL
a	NULL
protein	NULL
kinase	NULL
involved	NULL
in	NULL
post-transcriptional	NULL
activation	NULL
of	NULL
AP-1	NULL
,	NULL
which	NULL
is	NULL
known	NULL
to	NULL
bind	NULL
to	NULL
the	NULL
IL-2	NULL
gene	NULL
enhancer	NULL
(	NULL
Su	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

Relatively	NULL
little	NULL
is	NULL
known	NULL
about	NULL
the	NULL
early	NULL
signaling	NULL
pathway	NULL
triggered	NULL
by	NULL
CD28	NULL
.	NULL

A	NULL
hallmark	NULL
of	NULL
the	NULL
CD28	NULL
costimulus	NULL
is	NULL
its	NULL
refractoriness	NULL
to	NULL
the	NULL
immunosuppressants	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
(	NULL
June	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Bjorndahl	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
van	NULL
Lier	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

Consequently	NULL
,	NULL
signals	NULL
associated	NULL
with	NULL
TCR	NULL
activation	NULL
,	NULL
such	NULL
as	NULL
a	NULL
rise	NULL
in	NULL
cytosolic	NULL
free	NULL
calcium	NULL
,	NULL
formation	NULL
of	NULL
diacylglycerol	NULL
(	NULL
DAG	NULL
)	NULL
and	NULL
activation	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
(	NULL
PKC	NULL
)	NULL
,	NULL
are	NULL
typically	NULL
not	NULL
observed	NULL
in	NULL
response	NULL
to	NULL
B7	NULL
or	NULL
agonistic	NULL
anti-CD28	NULL
antibodies	NULL
.	NULL

Recently	NULL
,	NULL
CD28	NULL
stimulation	NULL
has	NULL
been	NULL
observed	NULL
to	NULL
lead	NULL
to	NULL
the	NULL
rapid	NULL
appearance	NULL
of	NULL
tyrosine-phosphorylated	NULL
proteins	NULL
,	NULL
including	NULL
the	NULL
CD28	NULL
molecule	NULL
itself	NULL
(	NULL
Lu	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
;	NULL
Vandenberghe	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
;	NULL
Hutchroft	NULL
and	NULL
Bierer	NULL
,	NULL
1994	NULL
;	NULL
Nunés	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

CD28-mediated	NULL
enhancement	NULL
3731	NULL
M.Los	NULL
et	NULL
al	NULL
.	NULL

&	NULL
1	NULL
2	NULL
3	NULL
4	NULL
$	NULL
«	NULL
&	NULL
$	NULL
$	NULL
¢	NULL
Q	NULL
‘	NULL
LQ	NULL
’	NULL
Q	NULL
A	NULL
(	NULL
739	NULL
(	NULL
$	NULL
9	NULL
(	NULL
$	NULL
6064	NULL
«	NULL
Q	NULL
-	NULL
P	NULL
$	NULL
8	NULL
®	NULL
+	NULL
&	NULL
¢	NULL
&	NULL
#	NULL
|	NULL
#	NULL
96	NULL
hid	NULL
<	NULL
th	NULL
{	NULL
“	NULL
“	NULL
w	NULL
6m	NULL
``	NULL
``	NULL
5C	NULL
|	NULL
|	NULL
C	NULL
#	NULL
o	NULL
w	NULL
U	NULL
®	NULL
1	NULL
2	NULL
B	NULL
405	NULL
5	NULL
3:4	NULL
``	NULL
%	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Characterization	NULL
of	NULL
the	NULL
CD28	NULL
costimulus	NULL
in	NULL
purified	NULL
T	NULL
lymphocytes	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Effects	NULL
on	NULL
IL-2	NULL
secretion	NULL
.	NULL

Cells	NULL
(	NULL
1x	NULL
10°	NULL
cells/ml	NULL
)	NULL
were	NULL
stimulated	NULL
for	NULL
48	NULL
h	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
saturating	NULL
concentrations	NULL
of	NULL
either	NULL
anti-CD28	NULL
,	NULL
anti-CD3	NULL
or	NULL
anti-CD28	NULL
+	NULL
anti-CD3	NULL
or	NULL
left	NULL
unstimulated	NULL
(	NULL
control	NULL
)	NULL
.	NULL

Supernatants	NULL
were	NULL
assayed	NULL
for	NULL
IL-2	NULL
using	NULL
an	NULL
ELISA	NULL
system	NULL
.	NULL

Results	NULL
are	NULL
given	NULL
in	NULL
IU/ml	NULL
+	NULL
SD	NULL
using	NULL
an	NULL
IL-2	NULL
standard	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Effect	NULL
of	NULL
CD28	NULL
stimulation	NULL
on	NULL
the	NULL
activation	NULL
of	NULL
CD28RC	NULL
.	NULL

Cells	NULL
were	NULL
stimulated	NULL
with	NULL
the	NULL
indicated	NULL
reagents	NULL
and	NULL
extracts	NULL
were	NULL
prepared	NULL
after	NULL
2	NULL
h.	NULL
Equal	NULL
amounts	NULL
of	NULL
protein	NULL
were	NULL
incubated	NULL
with	NULL
the	NULL
P-labeled	NULL
CD28RE	NULL
oligonucleotide	NULL
and	NULL
analyzed	NULL
by	NULL
EMSA	NULL
on	NULL
a	NULL
native	NULL
polyacrylamide	NULL
gel	NULL
.	NULL

The	NULL
arrowhead	NULL
indicates	NULL
the	NULL
position	NULL
of	NULL
the	NULL
CD28RE-specific	NULL
complex	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Competition	NULL
analysis	NULL
.	NULL

Reaction	NULL
mixtures	NULL
containing	NULL
extracts	NULL
of	NULL
anti-CD28	NULL
+	NULL
anti-CD3-stimulated	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
a	NULL
100-fold	NULL
excess	NULL
of	NULL
unlabeled	NULL
CD28RE	NULL
(	NULL
lane	NULL
2	NULL
)	NULL
,	NULL
a	NULL
xB-specific	NULL
oligonucleotide	NULL
from	NULL
the	NULL
mouse	NULL
K	NULL
light	NULL
chain	NULL
enhancer	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
an	NULL
unrelated	NULL
oligonucleotide	NULL
containing	NULL
the	NULL
SP1-binding	NULL
site	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
or	NULL
an	NULL
oligonucleotide	NULL
with	NULL
a	NULL
mutated	NULL
CD28RE	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

A	NULL
section	NULL
of	NULL
the	NULL
fluorogram	NULL
is	NULL
shown	NULL
.	NULL

(	NULL
D	NULL
)	NULL
Analysis	NULL
of	NULL
CD28RC	NULL
subunit	NULL
composition	NULL
.	NULL

Reaction	NULL
mixtures	NULL
of	NULL
an	NULL
extract	NULL
from	NULL
anti-CD28	NULL
+	NULL
anti-CD3-stimulated	NULL
cells	NULL
were	NULL
incubated	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
antibodies	NULL
raised	NULL
against	NULL
the	NULL
indicated	NULL
NF-KB	NULL
subunits	NULL
(	NULL
lanes	NULL
2-4	NULL
)	NULL
.	NULL

Lane	NULL
5	NULL
shows	NULL
the	NULL
results	NULL
with	NULL
an	NULL
unrelated	NULL
rabbit	NULL
IgG	NULL
antibody	NULL
.	NULL

A	NULL
section	NULL
of	NULL
the	NULL
fluorogram	NULL
is	NULL
shown	NULL
.	NULL

of	NULL
IL-2	NULL
production	NULL
and	NULL
cell	NULL
proliferation	NULL
was	NULL
prevented	NULL
by	NULL
the	NULL
tyrosine	NULL
kinase	NULL
inhibitor	NULL
herbimycin	NULL
A	NULL
,	NULL
suggesting	NULL
that	NULL
early	NULL
signaling	NULL
steps	NULL
are	NULL
controlled	NULL
by	NULL
still	NULL
unknown	NULL
protein	NULL
kinases	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
following	NULL
tyrosine	NULL
phosphorylation	NULL
of	NULL
CD28	NULL
,	NULL
formation	NULL
of	NULL
a	NULL
complex	NULL
with	NULL
phos-phatidylinositol-3-kinase	NULL
has	NULL
been	NULL
observed	NULL
which	NULL
binds	NULL
to	NULL
a	NULL
Tyr-Met-X-Met	NULL
motif	NULL
in	NULL
the	NULL
intracellular	NULL
part	NULL
of	NULL
CD28	NULL
(	NULL
Pagés	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Prasad	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
;	NULL
Truitt	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

However	NULL
,	NULL
it	NULL
is	NULL
presently	NULL
unknown	NULL
whether	NULL
3'-phosphorylated	NULL
phosphoinositides	NULL
,	NULL
the	NULL
products	NULL
of	NULL
this	NULL
lipid	NULL
kinase	NULL
,	NULL
represent	NULL
signaling	NULL
molecules	NULL
of	NULL
the	NULL
CD28	NULL
pathway	NULL
(	NULL
Lu	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

Other	NULL
messenger	NULL
systems	NULL
,	NULL
such	NULL
as	NULL
a	NULL
rise	NULL
in	NULL
cGMP	NULL
(	NULL
Ledbetter	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
)	NULL
or	NULL
phosphoinositol	NULL
levels	NULL
(	NULL
Ledbetter	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Nunés	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
,	NULL
appear	NULL
to	NULL
be	NULL
affected	NULL
by	NULL
the	NULL
degree	NULL
of	NULL
crosslinking	NULL
of	NULL
the	NULL
CD28	NULL
receptor	NULL
,	NULL
but	NULL
it	NULL
is	NULL
unlikely	NULL
that	NULL
these	NULL
molecules	NULL
are	NULL
essentially	NULL
required	NULL
for	NULL
the	NULL
costimulatory	NULL
pathway	NULL
involving	NULL
IL-2	NULL
secretion	NULL
.	NULL

Furthermore	NULL
,	NULL
most	NULL
studies	NULL
on	NULL
CD28	NULL
signaling	NULL
have	NULL
been	NULL
performed	NULL
in	NULL
T	NULL
lymphoma	NULL
cell	NULL
lines	NULL
.	NULL

Transformed	NULL
cells	NULL
,	NULL
however	NULL
,	NULL
may	NULL
be	NULL
poor	NULL
models	NULL
,	NULL
because	NULL
they	NULL
have	NULL
been	NULL
selected	NULL
to	NULL
grow	NULL
independently	NULL
from	NULL
costimulatory	NULL
signals	NULL
.	NULL

In	NULL
the	NULL
present	NULL
study	NULL
we	NULL
have	NULL
analyzed	NULL
the	NULL
early	NULL
events	NULL
of	NULL
CD28	NULL
activation	NULL
in	NULL
primary	NULL
T	NULL
lymphocytes	NULL
.	NULL

Since	NULL
most	NULL
effects	NULL
after	NULL
CD28	NULL
stimulation	NULL
are	NULL
only	NULL
observed	NULL
in	NULL
conjunction	NULL
with	NULL
TCR	NULL
activation	NULL
,	NULL
we	NULL
looked	NULL
for	NULL
a	NULL
unique	NULL
signal	NULL
that	NULL
was	NULL
predominantly	NULL
triggered	NULL
by	NULL
CD28	NULL
alone	NULL
.	NULL

We	NULL
found	NULL
that	NULL
CD28	NULL
stimulation	NULL
resulted	NULL
in	NULL
the	NULL
rapid	NULL
intracellular	NULL
formation	NULL
of	NULL
reactive	NULL
oxygen	NULL
intermediates	NULL
(	NULL
ROIs	NULL
)	NULL
which	NULL
have	NULL
recently	NULL
been	NULL
implicated	NULL
as	NULL
important	NULL
second	NULL
messenger	NULL
molecules	NULL
(	NULL
reviewed	NULL
by	NULL
Baeuerle	NULL
and	NULL
3732	NULL
Henkel	NULL
,	NULL
1994	NULL
;	NULL
Schulze-Osthoff	NULL
and	NULL
Baeuerle	NULL
,	NULL
1995	NULL
)	NULL
.	NULL

ROI	NULL
formation	NULL
by	NULL
CD28	NULL
involved	NULL
the	NULL
activation	NULL
of	NULL
S-lipoxygenase	NULL
and	NULL
inhibition	NULL
of	NULL
this	NULL
enzyme	NULL
was	NULL
able	NULL
to	NULL
block	NULL
activation	NULL
of	NULL
the	NULL
CD28-responsive	NULL
complex	NULL
and	NULL
IL-2	NULL
secretion	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
the	NULL
lipoxygenase	NULL
metabolite	NULL
leukotriene	NULL
B4	NULL
may	NULL
be	NULL
an	NULL
important	NULL
effector	NULL
molecule	NULL
of	NULL
the	NULL
CD28	NULL
signaling	NULL
pathway	NULL
.	NULL

Results	NULL
CD28	NULL
ligation	NULL
induces	NULL
IL-2	NULL
secretion	NULL
and	NULL
NF-xB	NULL
activation	NULL
To	NULL
investigate	NULL
the	NULL
biochemical	NULL
events	NULL
associated	NULL
with	NULL
CD28	NULL
signaling	NULL
,	NULL
primary	NULL
T	NULL
lymphocytes	NULL
were	NULL
treated	NULL
with	NULL
agonistic	NULL
anti-CD28	NULL
antibodies	NULL
,	NULL
with	NULL
and	NULL
without	NULL
anti-CD3	NULL
antibodies	NULL
activating	NULL
the	NULL
T	NULL
cell	NULL
receptor	NULL
(	NULL
TCR	NULL
)	NULL
complex	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Figure	NULL
1	NULL
A	NULL
,	NULL
ligation	NULL
of	NULL
neither	NULL
CD28	NULL
nor	NULL
the	NULL
TCR	NULL
led	NULL
to	NULL
a	NULL
significant	NULL
secretion	NULL
of	NULL
IL-2	NULL
into	NULL
the	NULL
supernatant	NULL
.	NULL

Combined	NULL
treatment	NULL
with	NULL
anti-CD28	NULL
and	NULL
anti-CD3	NULL
,	NULL
however	NULL
,	NULL
strongly	NULL
induced	NULL
IL-2	NULL
production	NULL
.	NULL

The	NULL
enhancement	NULL
of	NULL
IL-2	NULL
gene	NULL
expression	NULL
by	NULL
the	NULL
CD28	NULL
costimulus	NULL
has	NULL
been	NULL
found	NULL
to	NULL
be	NULL
mediated	NULL
by	NULL
the	NULL
CD28-responsive	NULL
element	NULL
(	NULL
CD28RE	NULL
)	NULL
localized	NULL
at	NULL
position	NULL
-162	NULL
to	NULL
-152	NULL
within	NULL
the	NULL
IL-2	NULL
promoter	NULL
(	NULL
Fraser	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
;	NULL
Verweij	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
)	NULL
.	NULL

After	NULL
costimulation	NULL
,	NULL
the	NULL
CD28RE	NULL
is	NULL
bound	NULL
by	NULL
a	NULL
CD28	NULL
response	NULL
complex	NULL
(	NULL
CD28RC	NULL
)	NULL
which	NULL
has	NULL
been	NULL
shown	NULL
to	NULL
contain	NULL
members	NULL
of	NULL
the	NULL
NF-KB	NULL
family	NULL
(	NULL
Costello	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Ghosh	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
(	NULL
EMSAs	NULL
)	NULL
demonstrated	NULL
that	NULL
stimulation	NULL
of	NULL
T	NULL
lymphocytes	NULL
with	NULL
anti-CD28	NULL
plus	NULL
anti-CD3	NULL
induced	NULL
a	NULL
CD28RE-binding	NULL
complex	NULL
that	NULL
was	NULL
not	NULL
detect	NULL
able	NULL
after	NULL
stimulation	NULL
with	NULL
either	NULL
agent	NULL
alone	NULL
(	NULL
Figure	NULL
1B	NULL
)	NULL
.	NULL

To	NULL
analyze	NULL
the	NULL
specificity	NULL
of	NULL
the	NULL
newly	NULL
formed	NULL
complex	NULL
,	NULL
competition	NULL
analyses	NULL
with	NULL
unlabeled	NULL
oligonucleotides	NULL
were	NULL
performed	NULL
.	NULL

Formation	NULL
of	NULL
the	NULL
slowly	NULL
migrating	NULL
CD28RC	NULL
was	NULL
competed	NULL
by	NULL
a	NULL
100-fold	NULL
excess	NULL
of	NULL
unlabeled	NULL
CD28RE	NULL
oligonucleotide	NULL
(	NULL
Figure	NULL
1C	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
but	NULL
not	NULL
by	NULL
an	NULL
unrelated	NULL
oligonucleotide	NULL
(	NULL
lane	NULL
4	NULL
)	NULL
or	NULL
by	NULL
an	NULL
oligonucleotide	NULL
mutated	NULL
in	NULL
the	NULL
CD28RE	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

DNA	NULL
binding	NULL
was	NULL
also	NULL
competed	NULL
by	NULL
an	NULL
oligonucleotide	NULL
with	NULL
a	NULL
classical	NULL
<	NULL
B-binding	NULL
site	NULL
(	NULL
Figure	NULL
1C	NULL
,	NULL
lane	NULL
3	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
CD28RC	NULL
consisted	NULL
of	NULL
members	NULL
of	NULL
the	NULL
NF-xB	NULL
family	NULL
.	NULL

NF-xB	NULL
complexes	NULL
may	NULL
constitute	NULL
a	NULL
variety	NULL
of	NULL
different	NULL
homo-	NULL
and	NULL
heterodimers	NULL
of	NULL
the	NULL
NF-KB-Rel	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
.	NULL

To	NULL
analyze	NULL
the	NULL
subunit	NULL
composition	NULL
of	NULL
the	NULL
CD28-induced	NULL
complex	NULL
,	NULL
supershift	NULL
assays	NULL
were	NULL
employed	NULL
.	NULL

Antibodies	NULL
against	NULL
the	NULL
NF-KB	NULL
subunits	NULL
p50	NULL
,	NULL
p65	NULL
and	NULL
c-Rel	NULL
were	NULL
added	NULL
to	NULL
an	NULL
extract	NULL
of	NULL
cells	NULL
stimulated	NULL
with	NULL
anti-CD28	NULL
and	NULL
anti-CD3	NULL
.	NULL

The	NULL
CD28-induced	NULL
DNA	NULL
binding	NULL
complex	NULL
was	NULL
totally	NULL
retarded	NULL
by	NULL
anti-p50	NULL
(	NULL
Figure	NULL
1D	NULL
,	NULL
lane	NULL
2	NULL
)	NULL
and	NULL
also	NULL
partially	NULL
by	NULL
anti-p65	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

Anti-c-Rel	NULL
caused	NULL
a	NULL
reduction	NULL
of	NULL
DNA	NULL
binding	NULL
(	NULL
Figure	NULL
1D	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
whereas	NULL
an	NULL
unrelated	NULL
(	NULL
anti-TNF	NULL
)	NULL
IgG	NULL
antibody	NULL
had	NULL
no	NULL
effect	NULL
(	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

These	NULL
data	NULL
indicate	NULL
the	NULL
presence	NULL
of	NULL
p50	NULL
,	NULL
p65	NULL
and	NULL
c-Rel	NULL
in	NULL
the	NULL
CD28-inducible	NULL
DNA	NULL
complex	NULL
.	NULL

CD28	NULL
ligation	NULL
induces	NULL
a	NULL
pro-oxidant	NULL
condition	NULL
in	NULL
T	NULL
lymphocytes	NULL
Biological	NULL
effects	NULL
of	NULL
CD28	NULL
,	NULL
such	NULL
as	NULL
IL-2	NULL
production	NULL
or	NULL
NF-KB	NULL
activation	NULL
,	NULL
can	NULL
be	NULL
observed	NULL
only	NULL
in	NULL
conjunction	NULL
with	NULL
TCR	NULL
activation	NULL
.	NULL

In	NULL
order	NULL
to	NULL
investigate	NULL
CD28-specific	NULL
signaling	NULL
events	NULL
we	NULL
looked	NULL
for	NULL
rapid	NULL
effects	NULL
that	NULL
could	NULL
be	NULL
monitored	NULL
solely	NULL
by	NULL
ligation	NULL
of	NULL
the	NULL
CD28	NULL
receptor	NULL
.	NULL

It	NULL
has	NULL
previously	NULL
been	NULL
reported	NULL
that	NULL
CD28-mediated	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B/CD28RC	NULL
is	NULL
prevented	NULL
by	NULL
antioxidants	NULL
,	NULL
suggesting	NULL
that	NULL
ROIs	NULL
are	NULL
involved	NULL
in	NULL
the	NULL
CD28	NULL
signaling	NULL
pathway	NULL
(	NULL
Costello	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Los	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

Measurement	NULL
of	NULL
intracellular	NULL
H	NULL
,	NULL
O	NULL
;	NULL
levels	NULL
by	NULL
FACS	NULL
analysis	NULL
with	NULL
the	NULL
dye	NULL
dichlorofluorescine	NULL
demonstrated	NULL
that	NULL
anti-CD28	NULL
alone	NULL
induced	NULL
a	NULL
strong	NULL
increase	NULL
of	NULL
intracellular	NULL
H	NULL
,	NULL
O	NULL
;	NULL
levels	NULL
(	NULL
Figure	NULL
2A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

This	NULL
oxidative	NULL
shift	NULL
was	NULL
detectable	NULL
within	NULL
5	NULL
min	NULL
after	NULL
cell	NULL
stimulation	NULL
and	NULL
was	NULL
maximal	NULL
after	NULL
30	NULL
min	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

An	NULL
isotype-matched	NULL
control	NULL
antibody	NULL
,	NULL
however	NULL
,	NULL
had	NULL
no	NULL
effects	NULL
(	NULL
Figure	NULL
2A	NULL
)	NULL
.	NULL

Production	NULL
of	NULL
H	NULL
,	NULL
O	NULL
,	NULL
was	NULL
significantly	NULL
weaker	NULL
after	NULL
stimulation	NULL
with	NULL
anti-CD3	NULL
whereas	NULL
the	NULL
combined	NULL
stimuli	NULL
resulted	NULL
in	NULL
additive	NULL
effects	NULL
.	NULL

In	NULL
parallel	NULL
,	NULL
we	NULL
analyzed	NULL
the	NULL
levels	NULL
of	NULL
intracellular	NULL
glutathione	NULL
(	NULL
GSH	NULL
)	NULL
,	NULL
the	NULL
major	NULL
cellular	NULL
antioxidant	NULL
,	NULL
using	NULL
FACS	NULL
analysis	NULL
of	NULL
monochlorobimane-stained	NULL
cells	NULL
(	NULL
Rice	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
)	NULL
.	NULL

Corresponding	NULL
to	NULL
the	NULL
increase	NULL
of	NULL
H	NULL
;	NULL
O	NULL
;	NULL
,	NULL
anti-CD28	NULL
alone	NULL
induced	NULL
a	NULL
rapid	NULL
decrease	NULL
of	NULL
GSH	NULL
(	NULL
Figure	NULL
2A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

This	NULL
decrease	NULL
was	NULL
visible	NULL
10	NULL
min	NULL
after	NULL
CD28	NULL
ligation	NULL
,	NULL
maximal	NULL
after	NULL
30	NULL
min	NULL
and	NULL
was	NULL
then	NULL
gradually	NULL
restored	NULL
within	NULL
12	NULL
h	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
results	NULL
demonstrate	NULL
that	NULL
CD28	NULL
signaling	NULL
is	NULL
associated	NULL
with	NULL
a	NULL
rapid	NULL
and	NULL
transient	NULL
shift	NULL
towards	NULL
pro-oxidant	NULL
conditions	NULL
.	NULL

Measurement	NULL
of	NULL
H	NULL
,	NULL
O	NULL
;	NULL
production	NULL
and	NULL
GSH	NULL
depletion	NULL
,	NULL
therefore	NULL
,	NULL
should	NULL
allow	NULL
us	NULL
to	NULL
delineate	NULL
the	NULL
sequence	NULL
of	NULL
biochemical	NULL
effects	NULL
triggered	NULL
upon	NULL
CD28	NULL
ligation	NULL
.	NULL

The	NULL
activation	NULL
of	NULL
receptor-associated	NULL
tyrosine	NULL
kinases	NULL
has	NULL
been	NULL
implicated	NULL
as	NULL
a	NULL
primary	NULL
step	NULL
of	NULL
CD28	NULL
activation	NULL
and	NULL
other	NULL
signaling	NULL
pathways	NULL
.	NULL

Treatment	NULL
of	NULL
T	NULL
lymphocytes	NULL
with	NULL
the	NULL
Src-like	NULL
kinase	NULL
inhibitor	NULL
herbimycin	NULL
A	NULL
has	NULL
been	NULL
Arachidonic	NULL
acid	NULL
metabolites	NULL
in	NULL
CD28	NULL
signaling	NULL
J	NULL
>	NULL
B	NULL
H202	NULL
H2O2	NULL
(	NULL
%	NULL
control	NULL
)	NULL
Relative	NULL
Cell	NULL
Number	NULL
GSH	NULL
(	NULL
%	NULL
control	NULL
)	NULL
Relative	NULL
Cell	NULL
Number	NULL
I	NULL
jg	NULL
!	NULL

&	NULL
é	NULL
109	NULL
101	NULL
102	NULL
103	NULL
&	NULL
,	NULL
Fluorescence	NULL
intensity	NULL
Q	NULL
:	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

Oxidative	NULL
events	NULL
in	NULL
response	NULL
to	NULL
CD28	NULL
activation	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Effects	NULL
of	NULL
anti-CD28	NULL
,	NULL
anti-CD3	NULL
,	NULL
anti-CD28	NULL
+	NULL
anti-CD3	NULL
and	NULL
of	NULL
an	NULL
isotype-matched	NULL
control	NULL
antibody	NULL
(	NULL
IgG1	NULL
)	NULL
on	NULL
intracellular	NULL
H	NULL
;	NULL
O	NULL
;	NULL
(	NULL
upper	NULL
panel	NULL
)	NULL
and	NULL
glutathione	NULL
levels	NULL
(	NULL
GSH	NULL
,	NULL
lower	NULL
panel	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
stimulated	NULL
for	NULL
30	NULL
min	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
indicated	NULL
reagents	NULL
or	NULL
left	NULL
untreated	NULL
(	NULL
Con	NULL
)	NULL
.	NULL

H	NULL
,	NULL
O	NULL
;	NULL
was	NULL
measured	NULL
by	NULL
FACS	NULL
analysis	NULL
of	NULL
dichlorofluorescine-stained	NULL
cells	NULL
,	NULL
GSH	NULL
was	NULL
determined	NULL
using	NULL
monochlorobimane	NULL
.	NULL

Results	NULL
are	NULL
given	NULL
as	NULL
percentage	NULL
+	NULL
SD	NULL
of	NULL
untreated	NULL
cells	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Comparative	NULL
FACS	NULL
profiles	NULL
of	NULL
unstimulated	NULL
(	NULL
white	NULL
area	NULL
)	NULL
and	NULL
anti-CD28-stimulated	NULL
cells	NULL
(	NULL
black	NULL
area	NULL
)	NULL
.	NULL

A	NULL
representative	NULL
measurement	NULL
of	NULL
H	NULL
;	NULL
O	NULL
;	NULL
levels	NULL
(	NULL
upper	NULL
panel	NULL
)	NULL
and	NULL
GSH	NULL
levels	NULL
(	NULL
lower	NULL
panel	NULL
)	NULL
is	NULL
shown	NULL
.	NULL

reported	NULL
to	NULL
inhibit	NULL
CD28-mediated	NULL
tyrosine	NULL
phosphorylation	NULL
and	NULL
IL-2	NULL
expression	NULL
(	NULL
Lu	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1992	NULL
;	NULL
Vandenberghe	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

In	NULL
accordance	NULL
,	NULL
anti-CD28-induced	NULL
H	NULL
;	NULL
0	NULL
;	NULL
production	NULL
and	NULL
GSH	NULL
depletion	NULL
(	NULL
Figure	NULL
3A	NULL
)	NULL
as	NULL
well	NULL
as	NULL
activation	NULL
of	NULL
NF-	NULL
«	NULL
B/CD28RC	NULL
(	NULL
Figure	NULL
3B	NULL
)	NULL
were	NULL
completely	NULL
inhibited	NULL
by	NULL
herbimycin	NULL
A	NULL
.	NULL

These	NULL
results	NULL
illustrate	NULL
that	NULL
oxidative	NULL
events	NULL
can	NULL
be	NULL
linked	NULL
to	NULL
early	NULL
steps	NULL
of	NULL
CD28	NULL
signaling	NULL
,	NULL
such	NULL
as	NULL
the	NULL
activation	NULL
of	NULL
tyrosine	NULL
kinases	NULL
.	NULL

Furthermore	NULL
,	NULL
certain	NULL
enzymes	NULL
producing	NULL
ROIs	NULL
upon	NULL
CD28	NULL
ligation	NULL
are	NULL
likely	NULL
to	NULL
act	NULL
downstream	NULL
of	NULL
tyrosine	NULL
kinases	NULL
.	NULL

Involvement	NULL
of	NULL
lipoxygenase	NULL
in	NULL
CD28	NULL
signaling	NULL
Several	NULL
enzymes	NULL
and	NULL
intracellular	NULL
electron	NULL
transfer	NULL
reactions	NULL
are	NULL
known	NULL
to	NULL
produce	NULL
ROIs	NULL
which	NULL
may	NULL
be	NULL
involved	NULL
in	NULL
intracellular	NULL
signaling	NULL
events	NULL
(	NULL
Halliwell	NULL
and	NULL
Gutteridge	NULL
,	NULL
1990	NULL
)	NULL
.	NULL

These	NULL
include	NULL
enzymes	NULL
involved	NULL
in	NULL
lipid	NULL
peroxidation	NULL
,	NULL
such	NULL
as	NULL
cyclooxygenase	NULL
and	NULL
lipoxygenase	NULL
,	NULL
the	NULL
mem-brane-bound	NULL
NADPH	NULL
oxidase	NULL
,	NULL
xanthine	NULL
oxidase	NULL
and	NULL
the	NULL
mitochondrial	NULL
respiratory	NULL
chain	NULL
.	NULL

To	NULL
identify	NULL
the	NULL
source	NULL
of	NULL
ROIs	NULL
produced	NULL
in	NULL
response	NULL
to	NULL
CD28	NULL
ligation	NULL
we	NULL
investigated	NULL
a	NULL
number	NULL
of	NULL
inhibitors	NULL
of	NULL
these	NULL
enzymes	NULL
for	NULL
an	NULL
effect	NULL
on	NULL
CD28-mediated	NULL
H	NULL
,	NULL
O	NULL
,	NULL
production	NULL
and	NULL
GSH	NULL
decrease	NULL
.	NULL

Initial	NULL
experiments	NULL
performed	NULL
in	NULL
primary	NULL
and	NULL
Jurkat	NULL
T	NULL
lymphocytes	NULL
revealed	NULL
that	NULL
neither	NULL
diphenylene	NULL
iodonium	NULL
,	NULL
an	NULL
inhibitor	NULL
of	NULL
NADPH	NULL
oxidase	NULL
,	NULL
nor	NULL
rotenone	NULL
,	NULL
a	NULL
respiratory	NULL
chain	NULL
inhibitor	NULL
,	NULL
nor	NULL
allopurinol	NULL
,	NULL
an	NULL
inhibitor	NULL
of	NULL
xanthine	NULL
oxidase	NULL
,	NULL
exerted	NULL
any	NULL
profound	NULL
effects	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

However	NULL
,	NULL
we	NULL
observed	NULL
that	NULL
in	NULL
particular	NULL
redox	NULL
inhibitors	NULL
3733	NULL
M.Los	NULL
et	NULL
al	NULL
.	NULL

A	NULL
180	NULL
--	NULL
I	NULL
-	NULL
--	NULL
-	NULL
(	NULL
%	NULL
control	NULL
)	NULL
|0.1109	NULL
H	NULL
O	NULL
,	NULL
(	NULL
Medium	NULL
1A	NULL
Medium	NULL
l	NULL
Herbimycin	NULL
A	NULL
«	NULL
10	NULL
2	NULL
B3	NULL
40	NULL
5060	NULL
7	NULL
8	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

Effects	NULL
of	NULL
the	NULL
tyrosine	NULL
kinase	NULL
inhibitor	NULL
herbimycin	NULL
A	NULL
on	NULL
CD28	NULL
signaling	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Effects	NULL
of	NULL
herbimycin	NULL
A	NULL
on	NULL
CD28-mediated	NULL
increase	NULL
of	NULL
intracellular	NULL
H	NULL
;	NULL
O	NULL
;	NULL
formation	NULL
(	NULL
left	NULL
panel	NULL
)	NULL
and	NULL
decrease	NULL
of	NULL
GSH	NULL
levels	NULL
(	NULL
right	NULL
panel	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
pretreated	NULL
for	NULL
8	NULL
h	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
herbimycin	NULL
A	NULL
(	NULL
HA	NULL
.	NULL

0.5	NULL
ug/ml	NULL
)	NULL
and	NULL
were	NULL
then	NULL
either	NULL
left	NULL
untreated	NULL
(	NULL
open	NULL
bars	NULL
)	NULL
or	NULL
stimulated	NULL
for	NULL
30	NULL
min	NULL
with	NULL
anti-CD28	NULL
(	NULL
black	NULL
bars	NULL
)	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Effects	NULL
of	NULL
herbimycin	NULL
A	NULL
on	NULL
the	NULL
activation	NULL
of	NULL
CD28RC	NULL
.	NULL

Cells	NULL
were	NULL
pretreated	NULL
as	NULL
described	NULL
in	NULL
(	NULL
A	NULL
)	NULL
and	NULL
then	NULL
stimulated	NULL
for	NULL
2	NULL
h	NULL
with	NULL
anti-CD28	NULL
,	NULL
anti-CD3	NULL
or	NULL
anti-CD28	NULL
+	NULL
anti-CD3	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
lanes	NULL
1-4	NULL
)	NULL
or	NULL
presence	NULL
of	NULL
herbimycin	NULL
A	NULL
(	NULL
HA	NULL
)	NULL
(	NULL
lanes	NULL
5-8	NULL
)	NULL
.	NULL

Lysates	NULL
were	NULL
analyzed	NULL
by	NULL
EMSA	NULL
using	NULL
a	NULL
P-labeled	NULL
CD28RE	NULL
oligonucleotide	NULL
.	NULL

A	NULL
section	NULL
of	NULL
the	NULL
fluorogram	NULL
is	NULL
shown	NULL
.	NULL

The	NULL
position	NULL
of	NULL
the	NULL
CD28RC-DNA	NULL
complex	NULL
is	NULL
indicated	NULL
by	NULL
an	NULL
arrowhead	NULL
.	NULL

of	NULL
lipid	NULL
peroxidation	NULL
,	NULL
such	NULL
as	NULL
butylated	NULL
hydroxyanisole	NULL
(	NULL
BHA	NULL
)	NULL
or	NULL
nordihydroguaiaretic	NULL
acid	NULL
(	NULL
NDGA	NULL
)	NULL
,	NULL
were	NULL
able	NULL
to	NULL
inhibit	NULL
CD28-mediated	NULL
oxidative	NULL
events	NULL
as	NULL
well	NULL
as	NULL
NF-xB	NULL
activation	NULL
and	NULL
IL-2	NULL
production	NULL
,	NULL
indicating	NULL
that	NULL
enzymes	NULL
of	NULL
lipid	NULL
peroxidation	NULL
may	NULL
be	NULL
involved	NULL
in	NULL
CD28	NULL
signaling	NULL
.	NULL

Figure	NULL
4	NULL
shows	NULL
that	NULL
the	NULL
methoxytetrahydropyran	NULL
compound	NULL
ICI	NULL
230487	NULL
,	NULL
a	NULL
potent	NULL
non-redox	NULL
inhibitor	NULL
of	NULL
lipoxygenase	NULL
(	NULL
Crawley	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
,	NULL
strongly	NULL
inhibited	NULL
CD28-induced	NULL
H	NULL
;	NULL
O	NULL
;	NULL
,	NULL
production	NULL
and	NULL
GSH	NULL
decrease	NULL
.	NULL

Another	NULL
compound	NULL
,	NULL
MK	NULL
886	NULL
,	NULL
which	NULL
inhibits	NULL
leukotriene	NULL
bio-synthesis	NULL
by	NULL
preventing	NULL
the	NULL
translocation	NULL
of	NULL
the	NULL
5-lipoxy-genase-activating	NULL
protein	NULL
(	NULL
FLAP	NULL
)	NULL
to	NULL
the	NULL
membrane	NULL
(	NULL
Rouzer	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
,	NULL
had	NULL
similar	NULL
effects	NULL
,	NULL
indicating	NULL
that	NULL
S-lipoxygenase	NULL
or	NULL
a	NULL
closely	NULL
related	NULL
lipoxygenase	NULL
may	NULL
be	NULL
involved	NULL
in	NULL
CD28	NULL
signaling	NULL
events	NULL
(	NULL
Figure	NULL
4	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
.	NULL

cyclooxygenases	NULL
which	NULL
have	NULL
been	NULL
also	NULL
reported	NULL
to	NULL
initiate	NULL
oxidative	NULL
stress	NULL
,	NULL
are	NULL
unlikely	NULL
to	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
CD28	NULL
signaling	NULL
pathway	NULL
.	NULL

Indomethacin	NULL
(	NULL
Figure	NULL
4	NULL
)	NULL
and	NULL
aspirin	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
,	NULL
two	NULL
unrelated	NULL
inhibitors	NULL
of	NULL
cyclo-oxygenase	NULL
,	NULL
did	NULL
not	NULL
inhibit	NULL
,	NULL
and	NULL
even	NULL
slightly	NULL
augmented	NULL
H	NULL
,	NULL
O	NULL
,	NULL
production	NULL
.	NULL

This	NULL
effect	NULL
might	NULL
be	NULL
explained	NULL
by	NULL
the	NULL
fact	NULL
that	NULL
inhibition	NULL
of	NULL
cyclooxygenase	NULL
leads	NULL
to	NULL
the	NULL
accumulation	NULL
of	NULL
arachidonic	NULL
acid	NULL
.	NULL

thereby	NULL
providing	NULL
increased	NULL
amounts	NULL
of	NULL
substrate	NULL
for	NULL
the	NULL
lipoxygenase	NULL
reaction	NULL
.	NULL

3734	NULL
180	NULL
4	NULL
g	NULL
B	NULL
1401	NULL
O	NULL
0	NULL
xe	NULL
l	NULL
o	NULL
100	NULL
1	NULL
cu	NULL
T	NULL
60	NULL
7	NULL
B	NULL
140	NULL
1207	NULL
2	NULL
€	NULL
8	NULL
1004	NULL
&	NULL
s	NULL
is	NULL
801	NULL
607	NULL
Medium	NULL
IC1	NULL
MK	NULL
886	NULL
Indo	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

Effects	NULL
of	NULL
lipoxygenase	NULL
and	NULL
cyclooxygenase	NULL
inhibitors	NULL
on	NULL
CD28-mediated	NULL
oxidative	NULL
events	NULL
.	NULL

Cells	NULL
were	NULL
pretreated	NULL
for	NULL
1	NULL
h	NULL
with	NULL
ICI	NULL
230487	NULL
(	NULL
ICI	NULL
,	NULL
5	NULL
uM	NULL
)	NULL
.	NULL

MK	NULL
886	NULL
(	NULL
1	NULL
uM	NULL
)	NULL
or	NULL
indomethacin	NULL
(	NULL
Indo	NULL
,	NULL
10	NULL
uM	NULL
)	NULL
and	NULL
then	NULL
either	NULL
left	NULL
unstimulated	NULL
(	NULL
open	NULL
bars	NULL
)	NULL
or	NULL
stimulated	NULL
with	NULL
anti-CD28	NULL
(	NULL
black	NULL
bars	NULL
)	NULL
for	NULL
30	NULL
min	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Effects	NULL
on	NULL
€D28-mediated	NULL
H	NULL
,	NULL
O	NULL
;	NULL
formation	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Effect	NULL
on	NULL
GSH	NULL
levels	NULL
.	NULL

CD28	NULL
ligation	NULL
triggers	NULL
arachidonic	NULL
acid	NULL
and	NULL
leukotriene	NULL
B4	NULL
release	NULL
The	NULL
lipoxygenase	NULL
pathway	NULL
is	NULL
coupled	NULL
to	NULL
phospholipase	NULL
A	NULL
;	NULL
(	NULL
PLA	NULL
;	NULL
)	NULL
which	NULL
provides	NULL
arachidonic	NULL
acid	NULL
for	NULL
leukotriene	NULL
biosynthesis	NULL
.	NULL

Inhibition	NULL
of	NULL
PLA	NULL
;	NULL
by	NULL
dexamethasone	NULL
significantly	NULL
inhibited	NULL
CD28-induced	NULL
production	NULL
of	NULL
HO	NULL
;	NULL
and	NULL
depletion	NULL
of	NULL
GSH	NULL
(	NULL
Figure	NULL
SA	NULL
)	NULL
.	NULL

The	NULL
involvement	NULL
of	NULL
PLA	NULL
;	NULL
in	NULL
the	NULL
CD28	NULL
signaling	NULL
cascade	NULL
was	NULL
further	NULL
demonstrated	NULL
by	NULL
measurement	NULL
of	NULL
arachidonic	NULL
acid	NULL
release	NULL
.	NULL

Stimulation	NULL
of	NULL
T	NULL
lymphocytes	NULL
with	NULL
anti-€CD28	NULL
resulted	NULL
in	NULL
a	NULL
strong	NULL
release	NULL
of	NULL
arachidonic	NULL
acid	NULL
whereas	NULL
anti-CD3	NULL
or	NULL
a	NULL
control	NULL
antibody	NULL
had	NULL
no	NULL
or	NULL
only	NULL
weak	NULL
effects	NULL
(	NULL
Figure	NULL
5B	NULL
)	NULL
.	NULL

Consistent	NULL
with	NULL
oxidative	NULL
events	NULL
,	NULL
CD28-triggered	NULL
arachidonic	NULL
acid	NULL
release	NULL
was	NULL
inhibited	NULL
by	NULL
dexamethasone	NULL
and	NULL
the	NULL
tyrosine	NULL
kinase	NULL
inhibitor	NULL
herbimycin	NULL
A	NULL
(	NULL
Figure	NULL
5B	NULL
)	NULL
,	NULL
whereas	NULL
inhibitors	NULL
of	NULL
lipoxygenase	NULL
had	NULL
no	NULL
effect	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

To	NULL
confirm	NULL
the	NULL
involvement	NULL
of	NULL
lipoxygenase	NULL
we	NULL
measured	NULL
the	NULL
production	NULL
of	NULL
leukotrienes	NULL
after	NULL
crosslinking	NULL
of	NULL
CD28	NULL
,	NULL
with	NULL
and	NULL
without	NULL
activation	NULL
of	NULL
the	NULL
TCR	NULL
.	NULL

Figure	NULL
5C	NULL
demonstrates	NULL
that	NULL
anti-CD28	NULL
induced	NULL
a	NULL
strong	NULL
increase	NULL
in	NULL
leukotriene	NULL
B4	NULL
(	NULL
LTB4	NULL
)	NULL
production	NULL
which	NULL
was	NULL
not	NULL
observed	NULL
after	NULL
stimulation	NULL
with	NULL
anti-CD3	NULL
or	NULL
a	NULL
control	NULL
antibody	NULL
.	NULL

Costimulation	NULL
by	NULL
both	NULL
agents	NULL
did	NULL
not	NULL
result	NULL
in	NULL
a	NULL
significant	NULL
difference	NULL
,	NULL
suggesting	NULL
that	NULL
lipoxygenase	NULL
was	NULL
selectively	NULL
activated	NULL
by	NULL
a	NULL
CD28-mediated	NULL
signal	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
time	NULL
course	NULL
experiments	NULL
revealed	NULL
that	NULL
the	NULL
production	NULL
of	NULL
LTB4	NULL
was	NULL
rapidly	NULL
induced	NULL
reaching	NULL
a	NULL
maximum	NULL
1	NULL
h	NULL
after	NULL
CD28	NULL
stimulation	NULL
(	NULL
Figure	NULL
5D	NULL
)	NULL
.	NULL

Liberation	NULL
of	NULL
other	NULL
lipoxygenase	NULL
products	NULL
.	NULL

such	NULL
as	NULL
the	NULL
peptidyl	NULL
leukotrienes	NULL
LTC4	NULL
,	NULL
LTD4	NULL
and	NULL
LTE4	NULL
,	NULL
however	NULL
,	NULL
was	NULL
not	NULL
significantly	NULL
increased	NULL
by	NULL
anti-CD28	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Furthermore	NULL
.	NULL

Arachidonic	NULL
acid	NULL
metabolites	NULL
in	NULL
CD28	NULL
signaling	NULL
A	NULL
180	NULL
C	NULL
250	NULL
-140	NULL
[	NULL
_J	NULL
Control	NULL
7	NULL
200	NULL
-	NULL
B	NULL
ant-co2s	NULL
§	NULL
140	NULL
|	NULL
L	NULL
_o	NULL
C	NULL
i	NULL
a	NULL
8	NULL
I	NULL
€	NULL
150	NULL
a	NULL
{	NULL
ico	NULL
®	NULL
a	NULL
a	NULL
a	NULL
<	NULL
0	NULL
S	NULL
&	NULL
100	NULL
o	NULL
100	NULL
-	NULL
a	NULL
-	NULL
!	NULL

7	NULL
T	NULL
L	NULL
9	NULL
.	NULL

7	NULL
50	NULL
I	NULL
60	NULL
-	NULL
-60	NULL
o	NULL
Medium	NULL
Dexa	NULL
Medium	NULL
Dexa	NULL
Medium	NULL
IC1	NULL
MK	NULL
886	NULL
g	NULL
180	NULL
4	NULL
[	NULL
J	NULL
Control	NULL
D	NULL
250	NULL
0	NULL
N	NULL
ani-cors	NULL
&	NULL
g	NULL
200	NULL
®	NULL
140	NULL
4	NULL
E4	NULL
=	NULL
E	NULL
€	NULL
150	NULL
mo	NULL
-	NULL
&	NULL
3	NULL
a	NULL
6	NULL
3	NULL
o	NULL
100	NULL
|	NULL
&	NULL
1004	NULL
&	NULL
-J	NULL
o	NULL
k=	NULL
>	NULL
50	NULL
4	NULL
8	NULL
<	NULL
60	NULL
J	NULL
0	NULL
Medium	NULL
__	NULL
«	NULL
CD3	NULL
HA	NULL
Dexa	NULL
IgG	NULL
0	NULL
0.5	NULL
1	NULL
2	NULL
4	NULL
Time	NULL
(	NULL
h	NULL
)	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

Involvement	NULL
of	NULL
phospholipase	NULL
A	NULL
;	NULL
and	NULL
lipoxygenase	NULL
in	NULL
CD28	NULL
signal	NULL
transduction	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Effect	NULL
of	NULL
the	NULL
phospholipase	NULL
A	NULL
;	NULL
inhibitor	NULL
dexamethasone	NULL
on	NULL
CD28-mediated	NULL
formation	NULL
of	NULL
H	NULL
;	NULL
O	NULL
;	NULL
(	NULL
left	NULL
panel	NULL
)	NULL
and	NULL
decrease	NULL
of	NULL
GSH	NULL
(	NULL
right	NULL
panel	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
left	NULL
untreated	NULL
or	NULL
treated	NULL
with	NULL
dexamethasone	NULL
(	NULL
Dexa	NULL
,	NULL
5	NULL
uM	NULL
)	NULL
for	NULL
8	NULL
h.	NULL
Unstimulated	NULL
(	NULL
open	NULL
bars	NULL
)	NULL
or	NULL
anti-CD28-treated	NULL
(	NULL
black	NULL
bars	NULL
)	NULL
cells	NULL
were	NULL
analyzed	NULL
30	NULL
min	NULL
after	NULL
stimulation	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Arachidonic	NULL
acid	NULL
release	NULL
assay	NULL
.	NULL

Cells	NULL
were	NULL
labeled	NULL
with	NULL
[	NULL
*HJarachidonic	NULL
acid	NULL
and	NULL
either	NULL
left	NULL
untreated	NULL
or	NULL
treated	NULL
with	NULL
herbimycin	NULL
A	NULL
(	NULL
HA	NULL
,	NULL
0.5	NULL
ug/ml	NULL
)	NULL
or	NULL
dexamethasone	NULL
(	NULL
Dexa	NULL
,	NULL
5	NULL
uM	NULL
)	NULL
.	NULL

8	NULL
h	NULL
later	NULL
,	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
anti-CD28	NULL
(	NULL
black	NULL
bars	NULL
)	NULL
or	NULL
medium	NULL
(	NULL
open	NULL
bars	NULL
)	NULL
,	NULL
with	NULL
or	NULL
without	NULL
anti-CD3	NULL
.	NULL

For	NULL
control	NULL
,	NULL
an	NULL
isotype-matched	NULL
control	NULL
antibody	NULL
(	NULL
IgG1	NULL
)	NULL
was	NULL
used	NULL
.	NULL

Arachidonic	NULL
acid	NULL
release	NULL
was	NULL
measured	NULL
following	NULL
2	NULL
h	NULL
of	NULL
stimulation	NULL
in	NULL
cell-free	NULL
supernatants	NULL
.	NULL

100	NULL
%	NULL
arachidonic	NULL
acid	NULL
release	NULL
corresponded	NULL
to	NULL
26	NULL
500	NULL
c.p.m	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Production	NULL
of	NULL
leukotriene	NULL
B4	NULL
(	NULL
LTB4	NULL
)	NULL
after	NULL
stimulation	NULL
with	NULL
anti-CD28	NULL
,	NULL
anti-CD3	NULL
and	NULL
anti-CD28	NULL
+	NULL
anti-CD3	NULL
and	NULL
effects	NULL
of	NULL
various	NULL
inhibitors	NULL
of	NULL
CD28	NULL
signaling	NULL
on	NULL
leukotriene	NULL
release	NULL
.	NULL

Cells	NULL
were	NULL
pretreated	NULL
with	NULL
herbimycin	NULL
A	NULL
(	NULL
HA	NULL
,	NULL
0.5	NULL
ug/ml	NULL
)	NULL
,	NULL
dexamethasone	NULL
(	NULL
Dexa	NULL
,	NULL
5	NULL
uM	NULL
)	NULL
,	NULL
ICI	NULL
230487	NULL
(	NULL
ICI	NULL
,	NULL
5	NULL
uM	NULL
)	NULL
,	NULL
MK	NULL
886	NULL
(	NULL
1	NULL
uM	NULL
)	NULL
or	NULL
indomethacin	NULL
(	NULL
Indo	NULL
,	NULL
10	NULL
uM	NULL
)	NULL
and	NULL
stimulated	NULL
with	NULL
(	NULL
black	NULL
bars	NULL
)	NULL
or	NULL
without	NULL
(	NULL
open	NULL
bars	NULL
)	NULL
anti-CD28	NULL
.	NULL

Release	NULL
of	NULL
leukotrienes	NULL
in	NULL
cell-free	NULL
supernatants	NULL
was	NULL
measured	NULL
by	NULL
an	NULL
ELISA	NULL
system	NULL
1	NULL
h	NULL
following	NULL
cell	NULL
stimulation	NULL
.	NULL

(	NULL
D	NULL
)	NULL
Time	NULL
course	NULL
of	NULL
LTB4	NULL
release	NULL
after	NULL
stimulation	NULL
with	NULL
anti-CD28	NULL
.	NULL

Cells	NULL
were	NULL
stimulated	NULL
with	NULL
1	NULL
ug/ml	NULL
anti-CD28	NULL
and	NULL
supernatants	NULL
were	NULL
harvested	NULL
after	NULL
the	NULL
indicated	NULL
time	NULL
points	NULL
.	NULL

pretreatment	NULL
of	NULL
T	NULL
cells	NULL
with	NULL
herbimycin	NULL
A	NULL
or	NULL
dexamethasone	NULL
strongly	NULL
inhibited	NULL
anti-CD28-induced	NULL
LTB4	NULL
release	NULL
(	NULL
Figure	NULL
5C	NULL
)	NULL
.	NULL

Corresponding	NULL
to	NULL
the	NULL
effects	NULL
observed	NULL
on	NULL
H	NULL
,	NULL
O	NULL
;	NULL
production	NULL
,	NULL
LTB4	NULL
release	NULL
was	NULL
nearly	NULL
completely	NULL
prevented	NULL
using	NULL
the	NULL
lipoxygenase	NULL
inhibitors	NULL
ICI	NULL
230487	NULL
and	NULL
MK	NULL
886	NULL
(	NULL
Figure	NULL
5C	NULL
)	NULL
.	NULL

Lipoxygenase	NULL
inhibition	NULL
specifically	NULL
affects	NULL
NF-xB/CD28SRC	NULL
activation	NULL
The	NULL
experiments	NULL
suggested	NULL
the	NULL
involvement	NULL
of	NULL
tyrosine	NULL
kinases	NULL
,	NULL
PLA	NULL
;	NULL
and	NULL
5-lipoxygenase	NULL
in	NULL
CD28	NULL
signaling	NULL
.	NULL

To	NULL
prove	NULL
the	NULL
functional	NULL
importance	NULL
of	NULL
these	NULL
molecules	NULL
,	NULL
we	NULL
investigated	NULL
the	NULL
effect	NULL
of	NULL
inhibition	NULL
of	NULL
these	NULL
pathways	NULL
on	NULL
CD28-mediated	NULL
activation	NULL
of	NULL
CD28RC	NULL
and	NULL
IL-2	NULL
production	NULL
.	NULL

Since	NULL
T	NULL
cells	NULL
respond	NULL
to	NULL
anti-CD28	NULL
by	NULL
ROI	NULL
formation	NULL
and	NULL
since	NULL
the	NULL
lipoxygenases	NULL
are	NULL
known	NULL
to	NULL
give	NULL
rise	NULL
to	NULL
elevated	NULL
ROI	NULL
formation	NULL
(	NULL
Gagnon	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Halliwell	NULL
and	NULL
Gutteridge	NULL
,	NULL
1990	NULL
)	NULL
,	NULL
we	NULL
also	NULL
analyzed	NULL
the	NULL
effects	NULL
of	NULL
the	NULL
antioxidant	NULL
pyrrolidine	NULL
dithiocarbamate	NULL
(	NULL
PDTC	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
to	NULL
the	NULL
glucocorticoid	NULL
receptor-dependent	NULL
PLA	NULL
;	NULL
inhibitor	NULL
_-	NULL
dexamethasone	NULL
,	NULL
_	NULL
p-bromophenacyl-bromide	NULL
(	NULL
BPB	NULL
)	NULL
was	NULL
included	NULL
as	NULL
an	NULL
unrelated	NULL
irreversible	NULL
inhibitor	NULL
of	NULL
PLA	NULL
;	NULL
(	NULL
Lister	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
.	NULL

To	NULL
this	NULL
end	NULL
,	NULL
T	NULL
lymphocytes	NULL
were	NULL
pretreated	NULL
with	NULL
herbimycin	NULL
A	NULL
,	NULL
dexamethasone	NULL
,	NULL
BPB	NULL
,	NULL
ICI	NULL
230487	NULL
,	NULL
MK	NULL
886	NULL
or	NULL
PDTC	NULL
and	NULL
then	NULL
stimulated	NULL
with	NULL
anti-CD28	NULL
and	NULL
anti-CD3	NULL
.	NULL

Non-toxic	NULL
concentrations	NULL
of	NULL
all	NULL
substances	NULL
effectively	NULL
inhibited	NULL
DNA	NULL
binding	NULL
activity	NULL
of	NULL
CD28RC	NULL
(	NULL
Figure	NULL
6A	NULL
)	NULL
as	NULL
well	NULL
as	NULL
anti-CD28-induced	NULL
IL-2	NULL
production	NULL
(	NULL
Figure	NULL
6B	NULL
)	NULL
.	NULL

This	NULL
indicated	NULL
that	NULL
activation	NULL
of	NULL
a	NULL
tyrosine	NULL
kinase	NULL
,	NULL
followed	NULL
by	NULL
activation	NULL
of	NULL
PLA	NULL
,	NULL
and	NULL
lipoxygenase	NULL
and	NULL
the	NULL
formation	NULL
of	NULL
ROIs	NULL
are	NULL
all	NULL
functionally	NULL
involved	NULL
in	NULL
CD28-triggered	NULL
biological	NULL
effects	NULL
.	NULL

T	NULL
cell	NULL
activation	NULL
and	NULL
IL-2	NULL
expression	NULL
is	NULL
subject	NULL
to	NULL
a	NULL
complex	NULL
regulation	NULL
by	NULL
a	NULL
number	NULL
of	NULL
transcription	NULL
factors	NULL
.	NULL

Notably	NULL
,	NULL
the	NULL
ubiquitous	NULL
factors	NULL
AP-1	NULL
and	NULL
NF-IL2A	NULL
(	NULL
which	NULL
is	NULL
indistinguishable	NULL
from	NULL
the	NULL
octamer	NULL
binding	NULL
factor	NULL
Oct-	NULL
1	NULL
)	NULL
as	NULL
well	NULL
as	NULL
the	NULL
T	NULL
cell-specific	NULL
transcription	NULL
factor	NULL
NF-AT	NULL
have	NULL
all	NULL
been	NULL
shown	NULL
to	NULL
be	NULL
critical	NULL
for	NULL
IL-2	NULL
expression	NULL
in	NULL
response	NULL
to	NULL
TCR	NULL
activation	NULL
(	NULL
Crabtree	NULL
and	NULL
Clipstone	NULL
,	NULL
1994	NULL
;	NULL
Rao	NULL
,	NULL
1994	NULL
)	NULL
.	NULL

To	NULL
examine	NULL
the	NULL
specificity	NULL
of	NULL
the	NULL
proposed	NULL
pathway	NULL
for	NULL
CD28	NULL
responses	NULL
,	NULL
we	NULL
monitored	NULL
the	NULL
effects	NULL
of	NULL
the	NULL
inhibitors	NULL
on	NULL
TCR-specific	NULL
transcription	NULL
factors	NULL
.	NULL

NF-IL2ZA	NULL
activity	NULL
was	NULL
constitutively	NULL
expressed	NULL
and	NULL
not	NULL
significantly	NULL
affected	NULL
by	NULL
TCR	NULL
and	NULL
CD28	NULL
crosslinking	NULL
nor	NULL
by	NULL
the	NULL
inhibitors	NULL
(	NULL
Figure	NULL
6C	NULL
)	NULL
.	NULL

DNA	NULL
binding	NULL
of	NULL
AP-1	NULL
and	NULL
NF-AT	NULL
was	NULL
induced	NULL
by	NULL
anti-CD3	NULL
but	NULL
not	NULL
further	NULL
enhanced	NULL
by	NULL
anti-CD28	NULL
(	NULL
Figure	NULL
6C	NULL
,	NULL
lanes	NULL
2-4	NULL
)	NULL
.	NULL

Herbimycin	NULL
A	NULL
strongly	NULL
prevented	NULL
DNA	NULL
binding	NULL
of	NULL
both	NULL
transcription	NULL
factors	NULL
which	NULL
3735	NULL
M.Los	NULL
et	NULL
al	NULL
.	NULL

<	NULL
4	NULL
CD28RC	NULL
Mediur	NULL
HA	NULL
Dexa	NULL
ic1	NULL
MK	NULL
886	NULL
_	NULL
PDTC	NULL
p	NULL
C	NULL
067	NULL
,	NULL
5	NULL
&	NULL
@	NULL
(	NULL
b	NULL
‘	NULL
L	NULL
@	NULL
b	NULL
a	NULL
CPG	NULL
G.	NULL
»	NULL
«	NULL
«	NULL
GPP	NULL
PFF	NULL
@	NULL
@	NULL
C	NULL
#	NULL
#	NULL
#	NULL
®	NULL
§Qm	NULL
4	NULL
aP-1	NULL
@	NULL
U-	NULL
<	NULL
-~	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
9	NULL
10	NULL
Fig	NULL
.	NULL

6	NULL
.	NULL

Effects	NULL
of	NULL
inhibitors	NULL
of	NULL
tyrosine	NULL
kinases	NULL
,	NULL
phospholipase	NULL
A	NULL
;	NULL
,	NULL
lipoxygenase	NULL
and	NULL
antioxidants	NULL
on	NULL
biological	NULL
activities	NULL
of	NULL
the	NULL
CD28	NULL
costimulus	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Effects	NULL
on	NULL
anti-CD28-induced	NULL
formation	NULL
of	NULL
CD28RC	NULL
.	NULL

Cells	NULL
were	NULL
pretreated	NULL
with	NULL
herbimycin	NULL
A	NULL
(	NULL
HA	NULL
,	NULL
0.5	NULL
ug/ml	NULL
)	NULL
,	NULL
dexamethasone	NULL
(	NULL
Dexa	NULL
,	NULL
5	NULL
M	NULL
)	NULL
,	NULL
p-bromophenacyl-bromide	NULL
(	NULL
BPB	NULL
,	NULL
100	NULL
uM	NULL
)	NULL
,	NULL
ICI	NULL
230487	NULL
(	NULL
ICI	NULL
,	NULL
5	NULL
uM	NULL
)	NULL
,	NULL
MK	NULL
886	NULL
(	NULL
1	NULL
uM	NULL
)	NULL
or	NULL
PDTC	NULL
(	NULL
5	NULL
uM	NULL
)	NULL
and	NULL
then	NULL
stimulated	NULL
for	NULL
2	NULL
h	NULL
with	NULL
a	NULL
combination	NULL
of	NULL
anti-CD3	NULL
and	NULL
anti-CD28	NULL
as	NULL
described	NULL
in	NULL
Figure	NULL
1B	NULL
.	NULL

Extracts	NULL
were	NULL
analyzed	NULL
by	NULL
EMSA	NULL
with	NULL
a	NULL
P-labeled	NULL
CD28RE	NULL
oligonucleotide	NULL
.	NULL

A	NULL
section	NULL
of	NULL
the	NULL
fluorogram	NULL
is	NULL
shown	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Effects	NULL
of	NULL
inhibitors	NULL
on	NULL
anti-CD3	NULL
+	NULL
anti-CD28-induced	NULL
IL-2	NULL
secretion	NULL
.	NULL

Cells	NULL
were	NULL
pretreated	NULL
with	NULL
the	NULL
inhibitors	NULL
and	NULL
then	NULL
stimulated	NULL
with	NULL
saturating	NULL
concentrations	NULL
of	NULL
anti-CD3	NULL
and	NULL
anti-CD28	NULL
or	NULL
left	NULL
unstimulated	NULL
(	NULL
control	NULL
)	NULL
.	NULL

IL-2	NULL
was	NULL
measured	NULL
in	NULL
the	NULL
supernatants	NULL
by	NULL
an	NULL
ELISA	NULL
48	NULL
h	NULL
after	NULL
stimulation	NULL
.	NULL

HA	NULL
:	NULL
0.5	NULL
pg/ml	NULL
herbimycin	NULL
A	NULL
;	NULL
Dexa	NULL
:	NULL
5	NULL
uM	NULL
dexamethasone	NULL
;	NULL
ICI	NULL
:	NULL
5	NULL
uM	NULL
ICI	NULL
230487	NULL
;	NULL
MK	NULL
886	NULL
:	NULL
5	NULL
uM	NULL
;	NULL
PDTC	NULL
:	NULL
5	NULL
uM	NULL
.	NULL

(	NULL
C	NULL
)	NULL
Effects	NULL
of	NULL
CD28	NULL
inhibitors	NULL
on	NULL
induction	NULL
of	NULL
AP-1	NULL
,	NULL
NF-AT	NULL
and	NULL
NF-IL-2A	NULL
DNA	NULL
binding	NULL
activity	NULL
.	NULL

Cells	NULL
were	NULL
incubated	NULL
with	NULL
the	NULL
indicated	NULL
inhibitors	NULL
as	NULL
described	NULL
in	NULL
(	NULL
A	NULL
)	NULL
.	NULL

Identical	NULL
extracts	NULL
as	NULL
in	NULL
(	NULL
A	NULL
)	NULL
were	NULL
used	NULL
for	NULL
EMSAs	NULL
.	NULL

Sections	NULL
of	NULL
the	NULL
fluorograms	NULL
are	NULL
shown	NULL
.	NULL

confirms	NULL
that	NULL
Src	NULL
tyrosine	NULL
protein	NULL
kinases	NULL
,	NULL
such	NULL
as	NULL
p56	NULL
!	NULL
``	NULL

and	NULL
p59	NULL
``	NULL
,	NULL
are	NULL
important	NULL
for	NULL
TCR	NULL
signal	NULL
transduction	NULL
(	NULL
Rincon	NULL
and	NULL
Flavell	NULL
,	NULL
1994	NULL
;	NULL
Weiss	NULL
and	NULL
Littman	NULL
,	NULL
1994	NULL
)	NULL
.	NULL

3736	NULL
2	NULL
(	NULL
IU/m	NULL
!	NULL
)	NULL

IL	NULL
Medium	NULL
LTB4	NULL
LTC4	NULL
b	NULL
p	NULL
p	NULL
&	NULL
©	NULL
%	NULL
X6	NULL
x09	NULL
6	NULL
p	NULL
)	NULL
®	NULL
&	NULL
O	NULL
®	NULL
$	NULL
&	NULL
&	NULL
Po	NULL
64	NULL
®	NULL
JJ	NULL
PJ	NULL
Fp	NULL
A	NULL
P	NULL
wo	NULL
®	NULL
an	NULL
ut	NULL
dd	NULL
8	NULL
O6	NULL
0	NULL
v	NULL
«	NULL
va	NULL
~	NULL
2	NULL
:	NULL
$	NULL
°4	NULL
56	NULL
6.7	NULL
B	NULL
$	NULL
Fig	NULL
.	NULL

7	NULL
.	NULL

Effects	NULL
of	NULL
exogenous	NULL
leukotrienes	NULL
on	NULL
IL-2	NULL
secretion	NULL
and	NULL
CD28RC	NULL
activation	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Effects	NULL
on	NULL
IL-2	NULL
secretion	NULL
.	NULL

T	NULL
lymphocytes	NULL
were	NULL
treated	NULL
with	NULL
50	NULL
nM	NULL
LTB4	NULL
or	NULL
LTC4	NULL
.	NULL

Supernatants	NULL
were	NULL
assessed	NULL
for	NULL
IL-2	NULL
48	NULL
h	NULL
after	NULL
cell	NULL
stimulation	NULL
.	NULL

(	NULL
B	NULL
)	NULL
Effects	NULL
on	NULL
CD28RC	NULL
activation	NULL
.	NULL

Cells	NULL
were	NULL
stimulated	NULL
with	NULL
the	NULL
indicated	NULL
reagents	NULL
and	NULL
50	NULL
nM	NULL
LTBA4	NULL
.	NULL

In	NULL
lanes	NULL
5-8	NULL
,	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
the	NULL
indicated	NULL
inhibitors	NULL
as	NULL
described	NULL
in	NULL
Figure	NULL
6A	NULL
and	NULL
then	NULL
treated	NULL
with	NULL
anti-CD3	NULL
and	NULL
LTB4	NULL
for	NULL
2	NULL
h.	NULL
A	NULL
section	NULL
of	NULL
the	NULL
flurogram	NULL
is	NULL
shown	NULL
.	NULL

Similar	NULL
to	NULL
CD28RC	NULL
,	NULL
both	NULL
factors	NULL
were	NULL
also	NULL
inhibited	NULL
by	NULL
dexamethasone	NULL
(	NULL
Figure	NULL
6C	NULL
,	NULL
lane	NULL
5	NULL
)	NULL
,	NULL
whereas	NULL
BPB	NULL
inhibited	NULL
CD28RC	NULL
but	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
AP-1	NULL
and	NULL
NF-AT	NULL
(	NULL
lane	NULL
6	NULL
)	NULL
.	NULL

This	NULL
suggested	NULL
that	NULL
dexamethasone	NULL
inhibited	NULL
both	NULL
transcription	NULL
factors	NULL
independently	NULL
of	NULL
PLA	NULL
;	NULL
involvement	NULL
.	NULL

Indeed	NULL
,	NULL
previous	NULL
reports	NULL
have	NULL
demonstrated	NULL
that	NULL
dexamethasone	NULL
downregulates	NULL
DNA	NULL
binding	NULL
of	NULL
AP-1	NULL
through	NULL
the	NULL
direct	NULL
interaction	NULL
of	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
with	NULL
AP-1	NULL
(	NULL
Jonat	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Vacca	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

NF-AT	NULL
which	NULL
consists	NULL
of	NULL
the	NULL
calcium/calcineurin-responsive	NULL
subunit	NULL
NF-ATp	NULL
and	NULL
newly	NULL
synthesized	NULL
AP-1	NULL
components	NULL
(	NULL
Rao	NULL
,	NULL
1994	NULL
)	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
be	NULL
also	NULL
inhibited	NULL
by	NULL
glucocorticoids	NULL
(	NULL
Paliogianni	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

However	NULL
,	NULL
unlike	NULL
CD28RC	NULL
,	NULL
AP-1	NULL
and	NULL
NF-AT	NULL
were	NULL
not	NULL
inhibited	NULL
by	NULL
the	NULL
two	NULL
lipoxygenase	NULL
inhibitors	NULL
(	NULL
Figure	NULL
6C	NULL
,	NULL
lanes	NULL
7-8	NULL
)	NULL
,	NULL
and	NULL
also	NULL
the	NULL
antioxidant	NULL
PDTC	NULL
exerted	NULL
no	NULL
significant	NULL
effects	NULL
(	NULL
lane	NULL
1	NULL
)	NULL
.	NULL

Thus	NULL
these	NULL
data	NULL
indicate	NULL
that	NULL
signaling	NULL
events	NULL
downstream	NULL
of	NULL
protein	NULL
tyrosine	NULL
phosphorylation	NULL
are	NULL
different	NULL
for	NULL
CD28RC	NULL
and	NULL
NF-AT	NULL
and	NULL
AP-1	NULL
,	NULL
respectively	NULL
.	NULL

LTB4	NULL
mimics	NULL
anti-CD28	NULL
effects	NULL
The	NULL
results	NULL
indicated	NULL
that	NULL
leukotrienes	NULL
,	NULL
such	NULL
as	NULL
LTB4	NULL
,	NULL
may	NULL
be	NULL
important	NULL
messenger	NULL
molecules	NULL
during	NULL
CD28	NULL
signal	NULL
transduction	NULL
.	NULL

We	NULL
therefore	NULL
investigated	NULL
whether	NULL
exogenous	NULL
leukotrienes	NULL
could	NULL
substitute	NULL
for	NULL
anti-CD28	NULL
effects	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Figure	NULL
7A	NULL
,	NULL
LTB4	NULL
slightly	NULL
induced	NULL
IL-2	NULL
secretion	NULL
,	NULL
whereas	NULL
LTC4	NULL
had	NULL
virtually	NULL
no	NULL
effects	NULL
.	NULL

Similar	NULL
to	NULL
the	NULL
CD28	NULL
costimulus	NULL
,	NULL
however	NULL
,	NULL
LTB4-induced	NULL
IL-2	NULL
production	NULL
was	NULL
potentiated	NULL
by	NULL
TCR	NULL
stimulation	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
analysis	NULL
of	NULL
CD28RC-DNA	NULL
binding	NULL
demonstrated	NULL
that	NULL
LTB4	NULL
,	NULL
when	NULL
added	NULL
in	NULL
combination	NULL
with	NULL
anti-CD3	NULL
,	NULL
could	NULL
mimic	NULL
anti	NULL
TCR	NULL
(	NULL
PTKs	NULL
)	NULL
.	NULL

para	NULL
_	NULL
lk	NULL
*	NULL
e	NULL
~	NULL
no	NULL
{	NULL
faSs	NULL
D	NULL
waw	NULL
~	NULL
-~	NULL
-	NULL
~	NULL
hia	NULL
22	NULL
(	NULL
PLC4y	NULL
)	NULL
*~	NULL
Raf	NULL
‘	NULL
w	NULL
/	NULL
\	NULL
rau	NULL
te	NULL
\\	NULL
``	NULL
a	NULL
*	NULL
(	NULL
MKK	NULL
}	NULL
DAG	NULL
[	NULL
Ca	NULL
#	NULL
+	NULL
]	NULL
U	NULL
Y	NULL
v	NULL
TMAFRR	NULL
fPKCt	NULL
(	NULL
Calcineurin	NULL
*	NULL
t	NULL
``	NULL
¥	NULL
Gene	NULL
Transcription	NULL
Arachidonic	NULL
acid	NULL
metabolites	NULL
in	NULL
CD28	NULL
signaling	NULL
CD28	NULL
(	NULL
PIL3K	NULL
)	NULL
``	NULL
\	NULL
@	NULL
.	NULL

T	NULL
Herbimycin	NULL
A	NULL
--	NULL
Dexamethasone	NULL
Bromophenacylbromide	NULL
5-LOX	NULL
I	NULL
|~____	NULL
¥	NULL
ROIs	NULL
‘	NULL
/—	NULL
Antioxidants	NULL
ICI	NULL
230487	NULL
MK	NULL
886	NULL
NF-xB/	NULL
CD28RC	NULL
Fig	NULL
.	NULL

8	NULL
.	NULL

Proposed	NULL
model	NULL
for	NULL
signal	NULL
transduction	NULL
by	NULL
CD28	NULL
.	NULL

CD28	NULL
ligation	NULL
activates	NULL
a	NULL
Src-related	NULL
protein	NULL
tyrosine	NULL
kinase	NULL
(	NULL
PTK	NULL
)	NULL
and	NULL
PI-3	NULL
kinase	NULL
(	NULL
PI-3K	NULL
)	NULL
as	NULL
initial	NULL
events	NULL
leading	NULL
to	NULL
the	NULL
stimulation	NULL
of	NULL
phospholipase	NULL
A	NULL
;	NULL
(	NULL
PLA	NULL
;	NULL
)	NULL
.	NULL

Formed	NULL
arachidonic	NULL
acid	NULL
is	NULL
a	NULL
substrate	NULL
for	NULL
S-lipoxygenase	NULL
(	NULL
5-LOX	NULL
)	NULL
to	NULL
generate	NULL
hydroxyeicosatetranoic	NULL
acids	NULL
and	NULL
leukotrienes	NULL
.	NULL

These	NULL
products	NULL
give	NULL
rise	NULL
to	NULL
the	NULL
formation	NULL
of	NULL
ROIs	NULL
which	NULL
then	NULL
activate	NULL
the	NULL
transcription	NULL
factor	NULL
Also	NULL
the	NULL
TCR	NULL
pathway	NULL
requires	NULL
the	NULL
initial	NULL
activation	NULL
of	NULL
PTKs	NULL
,	NULL
such	NULL
as	NULL
p56**	NULL
,	NULL
p59	NULL
``	NULL
and	NULL
ZAP-70	NULL
.	NULL

These	NULL
deliver	NULL
signals	NULL
that	NULL
are	NULL
coupled	NULL
to	NULL
at	NULL
least	NULL
three	NULL
pathways	NULL
including	NULL
p21	NULL
``	NULL
``	NULL
/MAP	NULL
kinase	NULL
(	NULL
MAPK	NULL
)	NULL
activation	NULL
,	NULL
stimulation	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
(	NULL
PKC	NULL
)	NULL
and	NULL
a	NULL
calcium/	NULL
calcineurin-dependent	NULL
signal	NULL
.	NULL

These	NULL
pathways	NULL
result	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
TCR-inducible	NULL
transcription	NULL
factors	NULL
AP-1	NULL
and	NULL
NF-AT	NULL
.	NULL

Although	NULL
the	NULL
signaling	NULL
cascade	NULL
differs	NULL
between	NULL
CD28	NULL
and	NULL
the	NULL
TCR	NULL
,	NULL
extensive	NULL
crosstalk	NULL
may	NULL
allow	NULL
complementation	NULL
and	NULL
synergy	NULL
resulting	NULL
in	NULL
full	NULL
IL-2	NULL
expression	NULL
:	NULL
CD28	NULL
may	NULL
cooperate	NULL
with	NULL
the	NULL
TCR	NULL
in	NULL
activation	NULL
of	NULL
p59	NULL
``	NULL
PTK	NULL
.	NULL

In	NULL
some	NULL
situations	NULL
,	NULL
CD28	NULL
ligation	NULL
triggers	NULL
a	NULL
calcium-dependent	NULL
signal	NULL
(	NULL
dashed	NULL
line	NULL
)	NULL
.	NULL

Diacylglycerol	NULL
(	NULL
DAG	NULL
)	NULL
formed	NULL
by	NULL
phospholipase	NULL
CyI	NULL
(	NULL
PLCy1	NULL
)	NULL
may	NULL
be	NULL
converted	NULL
by	NULL
DAG	NULL
lipase	NULL
to	NULL
arachidonic	NULL
acid	NULL
and	NULL
redirected	NULL
into	NULL
the	NULL
LOX	NULL
pathway	NULL
.	NULL

A	NULL
rise	NULL
in	NULL
cytosolic	NULL
free	NULL
calcium	NULL
may	NULL
activate	NULL
calcium-dependent	NULL
PLA	NULL
;	NULL
and	NULL
LOX	NULL
.	NULL

Furthermore	NULL
,	NULL
CD28-mediated	NULL
signals	NULL
may	NULL
be	NULL
enhanced	NULL
by	NULL
ROI	NULL
formation	NULL
through	NULL
the	NULL
TCR	NULL
which	NULL
may	NULL
be	NULL
induced	NULL
by	NULL
a	NULL
rise	NULL
in	NULL
calcium	NULL
or	NULL
PLCy	NULL
activation	NULL
.	NULL

CD28	NULL
effects	NULL
(	NULL
Figure	NULL
7B	NULL
,	NULL
lane	NULL
4	NULL
)	NULL
,	NULL
whereas	NULL
the	NULL
sole	NULL
addition	NULL
of	NULL
LTB4	NULL
to	NULL
T	NULL
lymphocytes	NULL
had	NULL
no	NULL
effects	NULL
(	NULL
lane	NULL
3	NULL
)	NULL
.	NULL

Activation	NULL
of	NULL
CD28RC	NULL
by	NULL
LTB4	NULL
was	NULL
considerably	NULL
weaker	NULL
than	NULL
in	NULL
response	NULL
to	NULL
anti-CD28	NULL
(	NULL
Figure	NULL
7B	NULL
,	NULL
compare	NULL
lanes	NULL
4	NULL
and	NULL
9	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
anti-CD28	NULL
responses	NULL
,	NULL
induction	NULL
of	NULL
DNA	NULL
binding	NULL
was	NULL
not	NULL
prevented	NULL
by	NULL
the	NULL
inhibitors	NULL
of	NULL
tyrosine	NULL
kinase	NULL
,	NULL
PLA	NULL
;	NULL
and	NULL
lipoxygenase	NULL
activity	NULL
(	NULL
Figure	NULL
7B	NULL
,	NULL
lanes	NULL
5-7	NULL
)	NULL
.	NULL

The	NULL
antioxidant	NULL
PDTC	NULL
,	NULL
however	NULL
,	NULL
completely	NULL
prevented	NULL
CD28RC	NULL
activation	NULL
in	NULL
response	NULL
to	NULL
LTB4	NULL
(	NULL
Figure	NULL
7B	NULL
,	NULL
lane	NULL
8	NULL
)	NULL
.	NULL

Thus	NULL
signals	NULL
elicited	NULL
after	NULL
CD28	NULL
ligation	NULL
can	NULL
obviously	NULL
be	NULL
at	NULL
least	NULL
partially	NULL
mimicked	NULL
by	NULL
exogenous	NULL
LTB4	NULL
.	NULL

Discussion	NULL
CD28	NULL
has	NULL
been	NULL
identified	NULL
as	NULL
a	NULL
costimulatory	NULL
receptor	NULL
that	NULL
provides	NULL
the	NULL
major	NULL
second	NULL
signal	NULL
necessary	NULL
for	NULL
T	NULL
cell	NULL
function	NULL
.	NULL

Despite	NULL
its	NULL
fundamental	NULL
importance	NULL
for	NULL
T	NULL
cell	NULL
development	NULL
and	NULL
the	NULL
immune	NULL
response	NULL
,	NULL
the	NULL
biochemical	NULL
basis	NULL
of	NULL
CD28	NULL
accessory	NULL
signals	NULL
is	NULL
poorly	NULL
understood	NULL
.	NULL

Most	NULL
studies	NULL
have	NULL
been	NULL
performed	NULL
in	NULL
transformed	NULL
T	NULL
cell	NULL
lines	NULL
which	NULL
may	NULL
be	NULL
unsuitable	NULL
since	NULL
they	NULL
may	NULL
bypass	NULL
costimulatory	NULL
signals	NULL
required	NULL
for	NULL
IL-2	NULL
expression	NULL
and	NULL
cell	NULL
proliferation	NULL
.	NULL

Identification	NULL
of	NULL
CD28-specific	NULL
second	NULL
messenger	NULL
molecules	NULL
is	NULL
further	NULL
hampered	NULL
by	NULL
the	NULL
fact	NULL
that	NULL
biological	NULL
effects	NULL
of	NULL
CD28	NULL
signaling	NULL
are	NULL
observed	NULL
only	NULL
in	NULL
conjunction	NULL
with	NULL
TCR	NULL
activation	NULL
.	NULL

Thus	NULL
a	NULL
central	NULL
question	NULL
is	NULL
whether	NULL
the	NULL
CD28	NULL
pathway	NULL
is	NULL
simply	NULL
enhancing	NULL
or	NULL
sustaining	NULL
the	NULL
signals	NULL
provided	NULL
by	NULL
the	NULL
TCR	NULL
or	NULL
whether	NULL
two	NULL
independent	NULL
pathways	NULL
exist	NULL
.	NULL

Triggering	NULL
of	NULL
the	NULL
TCR-CD3	NULL
complex	NULL
initiates	NULL
a	NULL
signal	NULL
cascade	NULL
that	NULL
leads	NULL
to	NULL
a	NULL
rise	NULL
in	NULL
cytosolic	NULL
free	NULL
calcium	NULL
,	NULL
formation	NULL
of	NULL
diacylglycerol	NULL
and	NULL
the	NULL
activation	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
and	NULL
other	NULL
kinases	NULL
(	NULL
Mueller	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Crabtree	NULL
and	NULL
Clipstone	NULL
,	NULL
1994	NULL
;	NULL
cf	NULL
.	NULL

Figure	NULL
8	NULL
)	NULL
.	NULL

This	NULL
calcium-dependent	NULL
pathway	NULL
is	NULL
blocked	NULL
by	NULL
the	NULL
immunosuppressive	NULL
calcineurin	NULL
inhibitors	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
.	NULL

A	NULL
characteristic	NULL
feature	NULL
of	NULL
the	NULL
CD28	NULL
pathway	NULL
is	NULL
its	NULL
refractoriness	NULL
to	NULL
cyclosporin	NULL
A	NULL
,	NULL
suggesting	NULL
that	NULL
CD28	NULL
triggers	NULL
an	NULL
independent	NULL
pathway	NULL
that	NULL
is	NULL
distinct	NULL
from	NULL
the	NULL
TCR	NULL
(	NULL
June	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

In	NULL
an	NULL
attempt	NULL
to	NULL
investigate	NULL
early	NULL
events	NULL
of	NULL
the	NULL
CD28	NULL
pathway	NULL
we	NULL
looked	NULL
for	NULL
signals	NULL
that	NULL
were	NULL
triggered	NULL
by	NULL
3737	NULL
M.Los	NULL
et	NULL
al	NULL
.	NULL

CD28	NULL
activation	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
TCR	NULL
ligation	NULL
.	NULL

We	NULL
found	NULL
that	NULL
treatment	NULL
of	NULL
peripheral	NULL
T	NULL
lymphocytes	NULL
with	NULL
anti-CD28	NULL
resulted	NULL
in	NULL
the	NULL
rapid	NULL
and	NULL
transient	NULL
increase	NULL
of	NULL
H	NULL
,	NULL
O	NULL
;	NULL
formation	NULL
which	NULL
was	NULL
paralleled	NULL
by	NULL
a	NULL
concomitant	NULL
depletion	NULL
of	NULL
the	NULL
antioxidant	NULL
glutathione	NULL
(	NULL
GSH	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
these	NULL
oxidative	NULL
events	NULL
were	NULL
less	NULL
pronounced	NULL
in	NULL
response	NULL
to	NULL
anti-CD3	NULL
.	NULL

In	NULL
order	NULL
to	NULL
identify	NULL
the	NULL
source	NULL
of	NULL
ROIs	NULL
produced	NULL
in	NULL
response	NULL
to	NULL
CD28	NULL
ligation	NULL
we	NULL
investigated	NULL
the	NULL
effects	NULL
of	NULL
inhibitors	NULL
of	NULL
several	NULL
biochemical	NULL
pathways	NULL
.	NULL

Pretreatment	NULL
of	NULL
T	NULL
lymphocytes	NULL
with	NULL
the	NULL
Src-like	NULL
tyrosine	NULL
kinase	NULL
inhibitor	NULL
herbimycin	NULL
A	NULL
significantly	NULL
inhibited	NULL
H	NULL
,	NULL
O	NULL
;	NULL
production	NULL
and	NULL
GSH	NULL
depletion	NULL
as	NULL
well	NULL
as	NULL
NF-KB/CD28RC	NULL
activation	NULL
and	NULL
IL-2	NULL
expression	NULL
.	NULL

This	NULL
is	NULL
in	NULL
line	NULL
with	NULL
previous	NULL
studies	NULL
indicating	NULL
that	NULL
tyrosine	NULL
phosphorylation	NULL
is	NULL
required	NULL
for	NULL
the	NULL
initiation	NULL
of	NULL
CD28	NULL
responses	NULL
(	NULL
Lu	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
;	NULL
Vandenberghe	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
;	NULL
Nunes	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

Inhibition	NULL
of	NULL
PLA	NULL
;	NULL
was	NULL
also	NULL
able	NULL
to	NULL
prevent	NULL
CD28-mediated	NULL
oxidative	NULL
events	NULL
and	NULL
IL-2	NULL
expression	NULL
,	NULL
though	NULL
to	NULL
a	NULL
lesser	NULL
extent	NULL
than	NULL
herbimycin	NULL
A	NULL
.	NULL

The	NULL
release	NULL
of	NULL
arachidonic	NULL
acid	NULL
was	NULL
observed	NULL
after	NULL
stimulation	NULL
with	NULL
anti-CD28	NULL
but	NULL
not	NULL
with	NULL
anti-CD3	NULL
.	NULL

Since	NULL
PLA	NULL
;	NULL
is	NULL
activated	NULL
by	NULL
protein	NULL
tyrosine	NULL
phosphorylation	NULL
,	NULL
it	NULL
can	NULL
be	NULL
suggested	NULL
that	NULL
arachidonic	NULL
acid	NULL
release	NULL
is	NULL
an	NULL
event	NULL
triggered	NULL
further	NULL
downstream	NULL
upon	NULL
CD28	NULL
ligation	NULL
.	NULL

Arachidonic	NULL
acid	NULL
is	NULL
converted	NULL
either	NULL
by	NULL
cyclooxygenases	NULL
to	NULL
prostaglandins	NULL
and	NULL
related	NULL
products	NULL
or	NULL
by	NULL
lipoxygenases	NULL
to	NULL
leukotrienes	NULL
.	NULL

Both	NULL
pathways	NULL
may	NULL
give	NULL
rise	NULL
to	NULL
intracellular	NULL
ROI	NULL
formation	NULL
(	NULL
Halliwell	NULL
and	NULL
Gutteridge	NULL
,	NULL
1990	NULL
)	NULL
.	NULL

Whereas	NULL
cyclooxygenase	NULL
inhibitors	NULL
,	NULL
such	NULL
as	NULL
indomethacin	NULL
and	NULL
aspirin	NULL
,	NULL
had	NULL
no	NULL
effects	NULL
,	NULL
various	NULL
unrelated	NULL
lipoxygenase	NULL
inhibitors	NULL
strongly	NULL
inhibited	NULL
CD28-mediated	NULL
signaling	NULL
.	NULL

These	NULL
included	NULL
the	NULL
traditionally	NULL
used	NULL
redox-dependent	NULL
inhibitors	NULL
NDGA	NULL
and	NULL
BHA	NULL
,	NULL
and	NULL
,	NULL
in	NULL
particular	NULL
,	NULL
the	NULL
recently	NULL
developed	NULL
compounds	NULL
MK	NULL
886	NULL
and	NULL
ICI	NULL
230487	NULL
,	NULL
which	NULL
selectively	NULL
inhibit	NULL
S-lipoxygenase	NULL
(	NULL
Rouzer	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Crawley	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

CD28	NULL
ligation	NULL
resulted	NULL
in	NULL
the	NULL
rapid	NULL
release	NULL
of	NULL
the	NULL
5-lipoxygenase	NULL
metabolite	NULL
LTB4	NULL
which	NULL
was	NULL
not	NULL
observed	NULL
in	NULL
response	NULL
to	NULL
TCR	NULL
stimulation	NULL
.	NULL

Of	NULL
note	NULL
,	NULL
the	NULL
time	NULL
course	NULL
of	NULL
LTB4	NULL
release	NULL
coincided	NULL
with	NULL
the	NULL
activation	NULL
of	NULL
NF-xB/CD28RC	NULL
.	NULL

We	NULL
further	NULL
observed	NULL
that	NULL
CD28-induced	NULL
NF-KB	NULL
activation	NULL
and	NULL
IL-2	NULL
release	NULL
were	NULL
completely	NULL
abolished	NULL
by	NULL
antioxidants	NULL
,	NULL
which	NULL
concurs	NULL
with	NULL
our	NULL
initial	NULL
observation	NULL
that	NULL
formation	NULL
of	NULL
a	NULL
pro-oxidant	NULL
condition	NULL
is	NULL
selective	NULL
for	NULL
the	NULL
CD28	NULL
response	NULL
.	NULL

Since	NULL
leukotriene	NULL
synthesis	NULL
involves	NULL
ROI	NULL
production	NULL
,	NULL
for	NULL
instance	NULL
in	NULL
the	NULL
metabolism	NULL
of	NULL
hydroxyeicosatetranoic	NULL
acids	NULL
(	NULL
Gagnon	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
,	NULL
ROI	NULL
formation	NULL
may	NULL
be	NULL
the	NULL
ultimate	NULL
step	NULL
leading	NULL
to	NULL
activation	NULL
.	NULL

Several	NULL
studies	NULL
have	NULL
shown	NULL
that	NULL
activation	NULL
of	NULL
NF-KB	NULL
in	NULL
response	NULL
to	NULL
other	NULL
stimuli	NULL
,	NULL
such	NULL
as	NULL
cytokines	NULL
or	NULL
lipopolysaccaride	NULL
,	NULL
is	NULL
abolished	NULL
by	NULL
antioxidants	NULL
(	NULL
Staal	NULL
et	NULL
a/	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Mihm	NULL
er	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
;	NULL
Schreck	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1991	NULL
;	NULL
Meyer	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Schulze-Osthoff	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
;	NULL
Schenk	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
,	NULL
suggesting	NULL
that	NULL
ROIs	NULL
may	NULL
represent	NULL
widely	NULL
used	NULL
second	NULL
messenger	NULL
molecules	NULL
.	NULL

However	NULL
,	NULL
the	NULL
mechanisms	NULL
by	NULL
which	NULL
ROIs	NULL
are	NULL
produced	NULL
in	NULL
response	NULL
to	NULL
these	NULL
various	NULL
NF-xB-activating	NULL
stimuli	NULL
have	NULL
not	NULL
carefully	NULL
been	NULL
investigated	NULL
so	NULL
far	NULL
.	NULL

In	NULL
the	NULL
case	NULL
of	NULL
TNF	NULL
,	NULL
it	NULL
has	NULL
been	NULL
shown	NULL
that	NULL
ROIs	NULL
produced	NULL
during	NULL
mitochondrial	NULL
respiration	NULL
are	NULL
involved	NULL
in	NULL
gene-inducing	NULL
effects	NULL
of	NULL
the	NULL
cytokine	NULL
(	NULL
Schulze-Osthoff	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

In	NULL
the	NULL
present	NULL
study	NULL
,	NULL
we	NULL
show	NULL
that	NULL
ROI	NULL
formation	NULL
in	NULL
response	NULL
to	NULL
anti-CD28	NULL
involves	NULL
5-lipoxygenase	NULL
or	NULL
a	NULL
closely	NULL
related	NULL
lipoxygenase	NULL
,	NULL
and	NULL
it	NULL
will	NULL
3738	NULL
be	NULL
interesting	NULL
to	NULL
examine	NULL
whether	NULL
other	NULL
inducers	NULL
of	NULL
NF-xB	NULL
converge	NULL
in	NULL
this	NULL
pathway	NULL
or	NULL
utilize	NULL
other	NULL
mechanisms	NULL
of	NULL
ROI	NULL
production	NULL
.	NULL

The	NULL
present	NULL
data	NULL
suggest	NULL
that	NULL
LTB4	NULL
is	NULL
an	NULL
important	NULL
intermediate	NULL
of	NULL
the	NULL
CD28	NULL
pathway	NULL
.	NULL

LTB4	NULL
is	NULL
a	NULL
pro-inflam-matory	NULL
lipid	NULL
which	NULL
exerts	NULL
several	NULL
biological	NULL
functions	NULL
(	NULL
reviewed	NULL
in	NULL
Samuelsson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Rola-Pleszezynski	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

In	NULL
monocytes	NULL
,	NULL
LTB4	NULL
was	NULL
found	NULL
to	NULL
induce	NULL
the	NULL
expression	NULL
of	NULL
TNF	NULL
,	NULL
IL-1	NULL
,	NULL
IL-6	NULL
and	NULL
the	NULL
IL-2	NULL
receptor	NULL
a	NULL
chain	NULL
by	NULL
both	NULL
transcriptional	NULL
and	NULL
post-transcriptional	NULL
mechanisms	NULL
(	NULL
Gagnon	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Rola-Pleszezynski	NULL
and	NULL
Stankova	NULL
,	NULL
1992	NULL
,	NULL
Stankova	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

Also	NULL
expression	NULL
of	NULL
these	NULL
genes	NULL
in	NULL
response	NULL
to	NULL
platelet-activating	NULL
factor	NULL
or	NULL
lipopolysaccharide	NULL
has	NULL
been	NULL
suggested	NULL
to	NULL
involve	NULL
endo-genous	NULL
LTB4	NULL
production	NULL
(	NULL
reviewed	NULL
in	NULL
Rola-Pleszczynksi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

In	NULL
monocytes	NULL
,	NULL
LTB4	NULL
can	NULL
directly	NULL
induce	NULL
NF-xB	NULL
activation	NULL
which	NULL
is	NULL
inhibited	NULL
by	NULL
antioxidants	NULL
(	NULL
Brach	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1992	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
investigated	NULL
whether	NULL
exo-genously	NULL
added	NULL
LTB4	NULL
could	NULL
substitute	NULL
for	NULL
the	NULL
CD28	NULL
costimulus	NULL
.	NULL

LTB4	NULL
did	NULL
indeed	NULL
induce	NULL
IL-2	NULL
production	NULL
and	NULL
NF-	NULL
«	NULL
B/CD28RC	NULL
activation	NULL
,	NULL
although	NULL
the	NULL
induction	NULL
was	NULL
considerably	NULL
weaker	NULL
than	NULL
anti-CD28	NULL
.	NULL

In	NULL
the	NULL
absence	NULL
of	NULL
anti-CD3	NULL
,	NULL
LTB4	NULL
had	NULL
no	NULL
effects	NULL
indicating	NULL
that	NULL
,	NULL
in	NULL
a	NULL
similar	NULL
fashion	NULL
to	NULL
the	NULL
CD28	NULL
signal	NULL
,	NULL
LTB4	NULL
provided	NULL
a	NULL
complementary	NULL
signal	NULL
for	NULL
TCR	NULL
pathway	NULL
.	NULL

The	NULL
activation	NULL
of	NULL
NF-xB	NULL
in	NULL
response	NULL
to	NULL
LTB4	NULL
could	NULL
be	NULL
inhibited	NULL
by	NULL
antioxidants	NULL
but	NULL
not	NULL
by	NULL
the	NULL
other	NULL
inhibitors	NULL
.	NULL

This	NULL
suggested	NULL
that	NULL
not	NULL
only	NULL
the	NULL
synthesis	NULL
of	NULL
LTB4	NULL
(	NULL
during	NULL
conversion	NULL
of	NULL
arachidonic	NULL
acid	NULL
to	NULL
endoperoxides	NULL
)	NULL
is	NULL
coupled	NULL
to	NULL
ROI	NULL
formation	NULL
,	NULL
but	NULL
also	NULL
LTB4	NULL
itself	NULL
may	NULL
cause	NULL
the	NULL
generation	NULL
of	NULL
ROIs	NULL
,	NULL
presumably	NULL
by	NULL
a	NULL
reverse	NULL
oxidizing	NULL
reaction	NULL
.	NULL

The	NULL
model	NULL
in	NULL
Figure	NULL
8	NULL
proposes	NULL
a	NULL
CD28	NULL
signaling	NULL
cascade	NULL
which	NULL
is	NULL
initiated	NULL
by	NULL
the	NULL
activation	NULL
of	NULL
a	NULL
still	NULL
unknown	NULL
Src-like	NULL
tyrosine	NULL
kinase	NULL
,	NULL
followed	NULL
by	NULL
the	NULL
activation	NULL
of	NULL
PLA	NULL
;	NULL
and	NULL
S-lipoxygenase	NULL
which	NULL
finally	NULL
leads	NULL
to	NULL
pro-oxidant-induced	NULL
activation	NULL
of	NULL
NF-KB/CD28RC	NULL
and	NULL
functional	NULL
IL-2	NULL
expression	NULL
.	NULL

The	NULL
proposed	NULL
pathway	NULL
differs	NULL
substantially	NULL
from	NULL
the	NULL
TCR	NULL
signaling	NULL
mechanism	NULL
.	NULL

To	NULL
analyze	NULL
the	NULL
specificity	NULL
for	NULL
CD28	NULL
,	NULL
we	NULL
monitored	NULL
the	NULL
effect	NULL
of	NULL
the	NULL
inhibitors	NULL
on	NULL
the	NULL
transcription	NULL
factors	NULL
NF-AT	NULL
and	NULL
AP-1	NULL
which	NULL
are	NULL
activated	NULL
by	NULL
TCR	NULL
ligation	NULL
and	NULL
not	NULL
further	NULL
induced	NULL
by	NULL
anti-CD28	NULL
.	NULL

Neither	NULL
lipoxygenase	NULL
inhibitors	NULL
nor	NULL
antioxidants	NULL
prevented	NULL
the	NULL
activation	NULL
of	NULL
these	NULL
TCR-inducible	NULL
transcription	NULL
factors	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
proposed	NULL
pathway	NULL
is	NULL
indeed	NULL
selective	NULL
for	NULL
CD28	NULL
.	NULL

However	NULL
,	NULL
despite	NULL
substantial	NULL
differences	NULL
between	NULL
both	NULL
pathways	NULL
,	NULL
extensive	NULL
crosstalk	NULL
and	NULL
interaction	NULL
may	NULL
exist	NULL
which	NULL
may	NULL
explain	NULL
the	NULL
synergistic	NULL
effect	NULL
of	NULL
TCR	NULL
and	NULL
CD28	NULL
stimulation	NULL
.	NULL

TCR	NULL
signaling	NULL
initially	NULL
involves	NULL
p56	NULL
``	NULL
,	NULL
p59	NULL
``	NULL
and	NULL
ZAP-70	NULL
tyrosine	NULL
kinases	NULL
,	NULL
followed	NULL
by	NULL
the	NULL
activation	NULL
of	NULL
the	NULL
p21	NULL
'	NULL
``	NULL
G-protein	NULL
,	NULL
phospholipase	NULL
Cy-mediated	NULL
phosphoinositol	NULL
turnover	NULL
,	NULL
calcium	NULL
release	NULL
and	NULL
activation	NULL
of	NULL
Ser/Thr	NULL
kinases	NULL
(	NULL
Crabtree	NULL
and	NULL
Clipstone	NULL
,	NULL
1994	NULL
;	NULL
Izquierdo	NULL
Pastor	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1995	NULL
)	NULL
.	NULL

It	NULL
is	NULL
conceivable	NULL
that	NULL
the	NULL
release	NULL
of	NULL
calcium	NULL
triggered	NULL
by	NULL
the	NULL
TCR	NULL
may	NULL
co-activate	NULL
PLA	NULL
,	NULL
and	NULL
S-lipoxygenase	NULL
which	NULL
are	NULL
dependent	NULL
on	NULL
calcium	NULL
ions	NULL
(	NULL
Samuelsson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Ford-Hutchinson	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

DAG	NULL
formed	NULL
by	NULL
TCR-activated	NULL
PLCy	NULL
may	NULL
be	NULL
converted	NULL
to	NULL
arachidonic	NULL
acid	NULL
by	NULL
DAG	NULL
lipase	NULL
and	NULL
thereby	NULL
redirected	NULL
to	NULL
the	NULL
lipoxygenase	NULL
pathway	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
it	NULL
has	NULL
been	NULL
found	NULL
recently	NULL
that	NULL
the	NULL
protein	NULL
phosphatase	NULL
calcineurin	NULL
may	NULL
be	NULL
involved	NULL
in	NULL
NF-xB	NULL
activation	NULL
in	NULL
T	NULL
cells	NULL
by	NULL
increasing	NULL
IB	NULL
degradation	NULL
(	NULL
Frantz	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1994	NULL
)	NULL
.	NULL

This	NULL
might	NULL
explain	NULL
the	NULL
observation	NULL
that	NULL
activation	NULL
of	NULL
NF-xB/CD28RC	NULL
requires	NULL
two	NULL
simultaneous	NULL
signals	NULL
and	NULL
that	NULL
neither	NULL
anti-CD28	NULL
nor	NULL
anti-CD3	NULL
alone	NULL
are	NULL
sufficient	NULL
to	NULL
induce	NULL
activation	NULL
.	NULL

In	NULL
summary	NULL
,	NULL
our	NULL
present	NULL
study	NULL
provides	NULL
important	NULL
new	NULL
details	NULL
about	NULL
the	NULL
mechanism	NULL
of	NULL
the	NULL
CD28	NULL
costimulus	NULL
.	NULL

Since	NULL
CD28	NULL
plays	NULL
an	NULL
essential	NULL
role	NULL
in	NULL
numerous	NULL
immune	NULL
and	NULL
inflammatory	NULL
processes	NULL
,	NULL
such	NULL
as	NULL
allograft	NULL
rejection	NULL
and	NULL
cytotoxic	NULL
T	NULL
cell	NULL
antitumor	NULL
response	NULL
,	NULL
selective	NULL
inhibition	NULL
or	NULL
potentiation	NULL
of	NULL
the	NULL
biochemical	NULL
events	NULL
described	NULL
may	NULL
be	NULL
useful	NULL
for	NULL
therapeutic	NULL
targeting	NULL
of	NULL
the	NULL
CD28	NULL
pathway	NULL
.	NULL

Materials	NULL
and	NULL
methods	NULL
Reagents	NULL
The	NULL
anti-CD28	NULL
monoclonal	NULL
antibody	NULL
LCB28	NULL
(	NULL
mouse	NULL
IgG	NULL
!	NULL
)	NULL

was	NULL
kindly	NULL
provided	NULL
by	NULL
Dr	NULL
R.van	NULL
Lier	NULL
(	NULL
Amsterdam	NULL
,	NULL
NL	NULL
)	NULL
.	NULL

Anti-CD3	NULL
(	NULL
OKT-3	NULL
)	NULL
was	NULL
obtained	NULL
from	NULL
the	NULL
American	NULL
Tissue	NULL
Culture	NULL
Collection	NULL
.	NULL

These	NULL
and	NULL
isotype-matched	NULL
control	NULL
antibodies	NULL
were	NULL
used	NULL
after	NULL
purification	NULL
by	NULL
protein	NULL
G	NULL
affinity	NULL
chromatography	NULL
.	NULL

The	NULL
lipoxygenase	NULL
inhibitors	NULL
ICI	NULL
230487	NULL
and	NULL
MK	NULL
886	NULL
were	NULL
provided	NULL
by	NULL
Dr	NULL
D.Steinhilber	NULL
(	NULL
Tiibingen	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

Dexamethasone	NULL
,	NULL
p-bromophenacyl-bromide	NULL
(	NULL
BPB	NULL
)	NULL
,	NULL
nordihydroguaiaretic	NULL
acid	NULL
(	NULL
NDGA	NULL
)	NULL
,	NULL
indomethacin	NULL
,	NULL
pyrrolidine	NULL
dithiocarbamate	NULL
(	NULL
PDTC	NULL
)	NULL
and	NULL
leukotrienes	NULL
were	NULL
from	NULL
Sigma	NULL
(	NULL
Deisenhofen	NULL
,	NULL
Germany	NULL
)	NULL
,	NULL
herbimycin	NULL
A	NULL
was	NULL
obtained	NULL
from	NULL
Biomol	NULL
(	NULL
Hamburg	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

Stock	NULL
solutions	NULL
of	NULL
the	NULL
reagents	NULL
were	NULL
routinely	NULL
prepared	NULL
in	NULL
DMSO/ethanol	NULL
(	NULL
1:1	NULL
)	NULL
and	NULL
used	NULL
in	NULL
dilutions	NULL
of	NULL
1:500	NULL
or	NULL
less	NULL
,	NULL
so	NULL
that	NULL
the	NULL
final	NULL
concentration	NULL
of	NULL
each	NULL
solvent	NULL
never	NULL
exceeded	NULL
0.1	NULL
%	NULL
.	NULL

Preparation	NULL
and	NULL
treatment	NULL
of	NULL
primary	NULL
T	NULL
lymphocytes	NULL
Venous	NULL
blood	NULL
was	NULL
collected	NULL
from	NULL
healthy	NULL
volunteers	NULL
,	NULL
drawn	NULL
in	NULL
heparin-treated	NULL
syringes	NULL
and	NULL
diluted	NULL
in	NULL
an	NULL
equal	NULL
volume	NULL
of	NULL
Hank	NULL
's	NULL
balanced	NULL
salt	NULL
solution	NULL
.	NULL

The	NULL
suspension	NULL
was	NULL
layered	NULL
over	NULL
a	NULL
Ficoll-Paque	NULL
cushion	NULL
(	NULL
Pharmacia	NULL
,	NULL
Freiburg	NULL
,	NULL
Germany	NULL
)	NULL
and	NULL
centrifuged	NULL
at	NULL
700	NULL
g	NULL
for	NULL
20	NULL
min	NULL
.	NULL

Mononuclear	NULL
cells	NULL
were	NULL
collected	NULL
at	NULL
the	NULL
interface	NULL
,	NULL
washed	NULL
twice	NULL
in	NULL
PBS	NULL
and	NULL
resuspended	NULL
in	NULL
RPMI-1640	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
FCS	NULL
and	NULL
antibiotics	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
incubated	NULL
on	NULL
nylon	NULL
wool	NULL
for	NULL
45	NULL
min	NULL
at	NULL
37°C	NULL
to	NULL
remove	NULL
monocytes	NULL
.	NULL

B	NULL
cells	NULL
were	NULL
depleted	NULL
by	NULL
incubation	NULL
with	NULL
anti-CD20-coated	NULL
magnetic	NULL
beads	NULL
(	NULL
Dynal	NULL
,	NULL
Hamburg	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

This	NULL
procedure	NULL
led	NULL
to	NULL
preparations	NULL
of	NULL
93-98	NULL
%	NULL
purified	NULL
T	NULL
lymphocytes	NULL
as	NULL
judged	NULL
by	NULL
flow	NULL
cytometry	NULL
with	NULL
anti-CD2	NULL
,	NULL
anti-CD14	NULL
and	NULL
anti-CD20	NULL
antibodies	NULL
.	NULL

Experiments	NULL
were	NULL
routinely	NULL
performed	NULL
12	NULL
h	NULL
after	NULL
T	NULL
cell	NULL
preparation	NULL
in	NULL
24-well	NULL
or	NULL
48-well	NULL
plates	NULL
,	NULL
in	NULL
a	NULL
volume	NULL
of	NULL
1	NULL
ml	NULL
or	NULL
0.5	NULL
ml	NULL
and	NULL
a	NULL
density	NULL
of	NULL
2.5	NULL
%	NULL
10°	NULL
cells/ml	NULL
.	NULL

Stimulation	NULL
with	NULL
anti-CD3	NULL
was	NULL
performed	NULL
after	NULL
precoating	NULL
the	NULL
plates	NULL
with	NULL
1	NULL
jig/ml	NULL
of	NULL
the	NULL
antibody	NULL
.	NULL

Anti-CD28	NULL
was	NULL
directly	NULL
added	NULL
to	NULL
the	NULL
cell	NULL
cultures	NULL
and	NULL
used	NULL
at	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
1	NULL
ug/ml	NULL
.	NULL

Fluorescent	NULL
measurement	NULL
of	NULL
intracellular	NULL
hydrogen	NULL
peroxide	NULL
Formation	NULL
of	NULL
hydrogen	NULL
peroxide	NULL
was	NULL
measured	NULL
using	NULL
dichlorofluorescin	NULL
diacetate	NULL
(	NULL
DFCH	NULL
)	NULL
according	NULL
to	NULL
Royall	NULL
and	NULL
Ischiropoulus	NULL
(	NULL
1993	NULL
)	NULL
.	NULL

A	NULL
10	NULL
mM	NULL
stock	NULL
solution	NULL
of	NULL
DFCH	NULL
(	NULL
Molecular	NULL
probes	NULL
,	NULL
Eugene	NULL
,	NULL
OR	NULL
)	NULL
was	NULL
prepared	NULL
in	NULL
DMSO	NULL
under	NULL
nitrogen	NULL
and	NULL
stored	NULL
at	NULL
-20°C	NULL
.	NULL

Cells	NULL
were	NULL
preloaded	NULL
with	NULL
5	NULL
uM	NULL
DFCH	NULL
in	NULL
culture	NULL
medium	NULL
for	NULL
0.5	NULL
h	NULL
at	NULL
37°C	NULL
.	NULL

Measurements	NULL
were	NULL
performed	NULL
in	NULL
duplicates	NULL
using	NULL
a	NULL
FACScan	NULL
(	NULL
Becton	NULL
Dickinson	NULL
)	NULL
flow	NULL
cytometer	NULL
.	NULL

Dead	NULL
cells	NULL
were	NULL
excluded	NULL
by	NULL
forward/side	NULL
scatter	NULL
gating	NULL
and	NULL
staining	NULL
with	NULL
propidium	NULL
iodide	NULL
.	NULL

Measurement	NULL
of	NULL
intracellular	NULL
glutathione	NULL
(	NULL
GSH	NULL
)	NULL
Intracellular	NULL
GSH	NULL
levels	NULL
were	NULL
determined	NULL
essentially	NULL
as	NULL
described	NULL
(	NULL
Rice	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
stained	NULL
with	NULL
20	NULL
uM	NULL
monochlorobimane	NULL
(	NULL
Molecular	NULL
Probes	NULL
)	NULL
for	NULL
10	NULL
min	NULL
at	NULL
37°C	NULL
.	NULL

The	NULL
staining	NULL
reaction	NULL
was	NULL
stopped	NULL
by	NULL
the	NULL
addition	NULL
of	NULL
ice-cold	NULL
PBS	NULL
.	NULL

Unreacted	NULL
dye	NULL
was	NULL
removed	NULL
by	NULL
centrifugation	NULL
of	NULL
the	NULL
cells	NULL
through	NULL
a	NULL
cushion	NULL
of	NULL
cold	NULL
FCS	NULL
and	NULL
two	NULL
washing	NULL
steps	NULL
in	NULL
cold	NULL
PBS	NULL
.	NULL

Samples	NULL
were	NULL
then	NULL
analyzed	NULL
in	NULL
duplicates	NULL
on	NULL
a	NULL
FACS	NULL
Vantage	NULL
(	NULL
Becton	NULL
Dickinson	NULL
)	NULL
flow	NULL
cytometry	NULL
system	NULL
using	NULL
an	NULL
emission	NULL
wavelength	NULL
of	NULL
455	NULL
nm	NULL
(	NULL
Omega	NULL
450DF-65	NULL
)	NULL
and	NULL
a	NULL
351-364	NULL
nm	NULL
bandpass	NULL
filter	NULL
for	NULL
excitation	NULL
.	NULL

Dead	NULL
cells	NULL
were	NULL
excluded	NULL
by	NULL
forward/side	NULL
scatter	NULL
gating	NULL
and	NULL
propidium	NULL
iodide	NULL
staining	NULL
.	NULL

Arachidonic	NULL
acid	NULL
release	NULL
assay	NULL
Cells	NULL
were	NULL
incubated	NULL
for	NULL
16	NULL
h	NULL
in	NULL
2	NULL
uCi/ml	NULL
!	NULL

[	NULL
5,6,8.9,1	NULL
1,12,14,15-Hj	NULL
}	NULL
arachi-donic	NULL
acid	NULL
(	NULL
190	NULL
mCi/mmol	NULL
,	NULL
Amersham	NULL
,	NULL
Braunschweig	NULL
,	NULL
Germany	NULL
)	NULL
and	NULL
pretreated	NULL
with	NULL
the	NULL
inhibitors	NULL
as	NULL
indicated	NULL
.	NULL

After	NULL
four	NULL
washing	NULL
steps	NULL
in	NULL
Arachidonic	NULL
acid	NULL
metabolites	NULL
in	NULL
CD28	NULL
signaling	NULL
culture	NULL
medium	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
anti-CD28	NULL
or	NULL
anti-CD3	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
inhibitors	NULL
.	NULL

Two	NULL
hours	NULL
later	NULL
,	NULL
supernatants	NULL
were	NULL
collected	NULL
,	NULL
centrifuged	NULL
at	NULL
700	NULL
g	NULL
for	NULL
10	NULL
min	NULL
and	NULL
at	NULL
10	NULL
000	NULL
g	NULL
for	NULL
15	NULL
min	NULL
.	NULL

Release	NULL
of	NULL
arachidonic	NULL
acid	NULL
in	NULL
the	NULL
supernatants	NULL
was	NULL
measured	NULL
by	NULL
liquid	NULL
scintillation	NULL
counting	NULL
.	NULL

Measurement	NULL
of	NULL
leukotrienes	NULL
and	NULL
IL-2	NULL
Cell-free	NULL
supernatants	NULL
of	NULL
T	NULL
lymphocytes	NULL
,	NULL
stimulated	NULL
for	NULL
48	NULL
h	NULL
,	NULL
were	NULL
assessed	NULL
for	NULL
IL-2	NULL
using	NULL
a	NULL
commercially	NULL
available	NULL
ELISA	NULL
system	NULL
(	NULL
Dianova	NULL
,	NULL
Hamburg	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

The	NULL
detection	NULL
limit	NULL
was	NULL
5	NULL
pg	NULL
IL-2/ml	NULL
.	NULL

Results	NULL
were	NULL
calculated	NULL
as	NULL
IU/ml	NULL
using	NULL
an	NULL
international	NULL
standard	NULL
prepara-tion	NULL
.	NULL

1	NULL
IU	NULL
IL-2/ml	NULL
corresponded	NULL
to	NULL
78	NULL
pg/ml	NULL
.	NULL

Leukotriene	NULL
release	NULL
was	NULL
measured	NULL
1	NULL
h	NULL
after	NULL
cell	NULL
stimulation	NULL
using	NULL
a	NULL
competitive	NULL
ELISA	NULL
system	NULL
for	NULL
LTB4	NULL
and	NULL
LTC4	NULL
,	NULL
LTD4	NULL
and	NULL
LTE4	NULL
(	NULL
BIOTRAK	NULL
,	NULL
Amersham	NULL
)	NULL
.	NULL

The	NULL
detection	NULL
limit	NULL
was	NULL
6.2	NULL
pg	NULL
/ml	NULL
for	NULL
LTB4	NULL
and	NULL
10	NULL
pg/ml	NULL
for	NULL
LTC4	NULL
,	NULL
LTD4	NULL
and	NULL
LTE4	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
For	NULL
detection	NULL
of	NULL
DNA	NULL
binding	NULL
activities	NULL
cells	NULL
were	NULL
seeded	NULL
in	NULL
a	NULL
2	NULL
ml	NULL
volume	NULL
at	NULL
2.5	NULL
%	NULL
10°	NULL
cells/ml	NULL
and	NULL
pretreated	NULL
with	NULL
the	NULL
inhibitors	NULL
for	NULL
1	NULL
h	NULL
and	NULL
in	NULL
the	NULL
case	NULL
of	NULL
dexamethasone	NULL
and	NULL
herbimycin	NULL
A	NULL
(	NULL
Uehara	NULL
and	NULL
Fukazawa	NULL
,	NULL
1991	NULL
)	NULL
for	NULL
8	NULL
h.	NULL
Then	NULL
the	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
anti-CD28	NULL
or	NULL
anti-CD3	NULL
.	NULL

After	NULL
a	NULL
further	NULL
2	NULL
h	NULL
of	NULL
incubation	NULL
cells	NULL
were	NULL
washed	NULL
with	NULL
ice-cold	NULL
PBS	NULL
and	NULL
total	NULL
and	NULL
nuclear	NULL
cell	NULL
extracts	NULL
were	NULL
prepared	NULL
essentially	NULL
as	NULL
described	NULL
(	NULL
Schulze-Osthoff	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1993	NULL
)	NULL
.	NULL

Equal	NULL
amounts	NULL
of	NULL
the	NULL
extracts	NULL
(	NULL
~10	NULL
ug	NULL
crude	NULL
protein	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
the	NULL
oligonucleotides	NULL
.	NULL

Binding	NULL
reactions	NULL
were	NULL
performed	NULL
in	NULL
a	NULL
20	NULL
ull	NULL
volume	NULL
containing	NULL
2-4	NULL
pl	NULL
of	NULL
extract	NULL
,	NULL
4	NULL
pul	NULL
5	NULL
%	NULL
binding	NULL
buffer	NULL
(	NULL
20	NULL
mM	NULL
HEPES	NULL
pH	NULL
7.5	NULL
,	NULL
50	NULL
mM	NULL
KCl	NULL
,	NULL
1	NULL
mM	NULL
DTT	NULL
,	NULL
2.5	NULL
mM	NULL
MgCl	NULL
»	NULL
,	NULL
20	NULL
%	NULL
Ficoll	NULL
)	NULL
,	NULL
2	NULL
ug	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
as	NULL
non-specific	NULL
competitor	NULL
DNA	NULL
,	NULL
2	NULL
pug	NULL
BSA	NULL
and	NULL
10	NULL
000-15	NULL
000	NULL
c.p.m	NULL
.	NULL

Cerenkov	NULL
of	NULL
the	NULL
labeled	NULL
oligonucleotide	NULL
.	NULL

Binding	NULL
reactions	NULL
for	NULL
NF-AT	NULL
were	NULL
performed	NULL
with	NULL
200	NULL
ng	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
per	NULL
reaction	NULL
.	NULL

After	NULL
30	NULL
min	NULL
incubation	NULL
at	NULL
room	NULL
temperature	NULL
,	NULL
samples	NULL
were	NULL
loaded	NULL
on	NULL
a	NULL
4	NULL
%	NULL
non-denaturing	NULL
polyacrylamide	NULL
get	NULL
and	NULL
run	NULL
in	NULL
0.5	NULL
%	NULL
TBE	NULL
buffer	NULL
pH	NULL
8.3	NULL
.	NULL

For	NULL
supershift	NULL
assays	NULL
,	NULL
2	NULL
pil	NULL
of	NULL
antibody	NULL
was	NULL
added	NULL
to	NULL
the	NULL
reaction	NULL
mixture	NULL
simultaneously	NULL
with	NULL
the	NULL
protein	NULL
and	NULL
the	NULL
mixture	NULL
was	NULL
incubated	NULL
as	NULL
described	NULL
above	NULL
.	NULL

Anti-p50	NULL
,	NULL
anti-p65	NULL
and	NULL
anti-c-Rel	NULL
were	NULL
purchased	NULL
from	NULL
Santa	NULL
Cruz	NULL
Biotechnology	NULL
(	NULL
Santa	NULL
Cruz	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

The	NULL
sense	NULL
sequences	NULL
of	NULL
the	NULL
oligonucleotides	NULL
were	NULL
as	NULL
follows	NULL
:	NULL
(	NULL
a	NULL
)	NULL
CD28RE	NULL
(	NULL
CD28-responsive	NULL
element	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
)	NULL
5-GATCTGGTTTAAAGAAATTCCAAAGAG-3	NULL
``	NULL
(	NULL
b	NULL
)	NULL
CD28REmut	NULL
(	NULL
mutated	NULL
CD28RE	NULL
)	NULL
5'-GATCTGGTTITAAAGAAGCCTCAAAGAG-3	NULL
'	NULL
(	NULL
c	NULL
)	NULL
xB	NULL
(	NULL
NF-xB	NULL
binding	NULL
site	NULL
of	NULL
the	NULL
mouse	NULL
Ig	NULL
x	NULL
light	NULL
chain	NULL
enhancer	NULL
)	NULL
5'-AGCTTCAGAGGGGATTTCCGAGAGG-3	NULL
'	NULL
(	NULL
d	NULL
)	NULL
SPI	NULL
5'-ATTCGATCGGGGCGGGGCGAGC-3	NULL
'	NULL
(	NULL
e	NULL
)	NULL
AP-1	NULL
(	NULL
TRE-responsive	NULL
element	NULL
of	NULL
the	NULL
collagenase	NULL
promoter	NULL
)	NULL
5'-AGCTTGATGAGTCAGGCCGGATC-3	NULL
'	NULL
(	NULL
f	NULL
)	NULL
NF-AT	NULL
(	NULL
distal	NULL
NF-AT	NULL
binding	NULL
site	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
)	NULL
5-GGAGGAAAAACTGTTTCATACAGAAGGCGT-3	NULL
'	NULL
(	NULL
g	NULL
)	NULL
NF-IL2A	NULL
(	NULL
proximal	NULL
octamer	NULL
binding	NULL
site	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
)	NULL
5'-TAATATGTAAAAACATT-3	NULL
'	NULL
Acknowledgements	NULL
The	NULL
authors	NULL
wish	NULL
to	NULL
thank	NULL
R.van	NULL
Lier	NULL
and	NULL
K.Khazaie	NULL
for	NULL
providing	NULL
anti-CD28	NULL
and	NULL
anti-CD3	NULL
antibodies	NULL
,	NULL
D.Steinhilber	NULL
for	NULL
lipoxygenase	NULL
inhibitors	NULL
,	NULL
M.Li-Weber	NULL
for	NULL
oligonucleotides	NULL
,	NULL
M.Pach	NULL
for	NULL
antibody	NULL
purification	NULL
,	NULL
and	NULL
A.Bohme	NULL
and	NULL
H.	NULL
Walczak	NULL
for	NULL
critical	NULL
reading	NULL
the	NULL
manuscript	NULL
.	NULL

References	NULL
Aruffo	NULL
,	NULL
A	NULL
.	NULL

and	NULL
Seed	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
84	NULL
,	NULL
8573-8577	NULL
.	NULL

Baeuerle	NULL
,	NULL
P.A	NULL
.	NULL

and	NULL
Henkel	NULL
,	NULL
T	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
12	NULL
,	NULL
141-179	NULL
.	NULL

BjorndahlL	NULL
,	NULL
J.M	NULL
.	NULL

,	NULL
Sung	NULL
,	NULL
S.-S.J	NULL
.	NULL

,	NULL
Hansen	NULL
,	NULL
J.A	NULL
.	NULL

and	NULL
Fu	NULL
,	NULL
S.M	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Eur	NULL
J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
19	NULL
,	NULL
881-887	NULL
.	NULL

Brach	NULL
,	NULL
M.A	NULL
.	NULL

,	NULL
de	NULL
Vos	NULL
,	NULL
S..	NULL
Amnold	NULL
,	NULL
C.	NULL
,	NULL
GrufB	NULL
,	NULL
H.-J	NULL
.	NULL

,	NULL
Mertelsmann	NULL
,	NULL
R	NULL
.	NULL

and	NULL
Herrmann	NULL
,	NULL
F	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Eur	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
22	NULL
,	NULL
2705-2711	NULL
.	NULL

Cerdan	NULL
,	NULL
C.	NULL
,	NULL
Martin	NULL
,	NULL
Y.	NULL
,	NULL
Brailly	NULL
,	NULL
H.	NULL
,	NULL
Courcoul	NULL
,	NULL
M.	NULL
,	NULL
Flavetta	NULL
,	NULL
S.	NULL
,	NULL
Costello	NULL
,	NULL
R.	NULL
,	NULL
Mawas	NULL
,	NULL
C.	NULL
,	NULL
Birg.F	NULL
.	NULL

and	NULL
Olive	NULL
,	NULL
D	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
146	NULL
,	NULL
560-564	NULL
.	NULL

Cerdan	NULL
,	NULL
C.	NULL
,	NULL
Martin	NULL
,	NULL
Y.	NULL
,	NULL
Courcoul	NULL
,	NULL
M.	NULL
,	NULL
Mawas	NULL
,	NULL
C.	NULL
,	NULL
Birg	NULL
,	NULL
F	NULL
.	NULL

and	NULL
Olive	NULL
,	NULL
D	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
149	NULL
,	NULL
2255-2261	NULL
.	NULL

3739	NULL
M.Los	NULL
et	NULL
al	NULL
.	NULL

Costello	NULL
,	NULL
R.	NULL
,	NULL
Lipcey	NULL
,	NULL
C.	NULL
,	NULL
Algarté	NULL
,	NULL
M.	NULL
,	NULL
Cerdan	NULL
,	NULL
C.	NULL
,	NULL
Baeuerle	NULL
,	NULL
P.A	NULL
.	NULL

,	NULL
Olive	NULL
,	NULL
D	NULL
.	NULL

and	NULL
Imbert	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Cell	NULL
Growth	NULL
Differ	NULL
.	NULL

,	NULL
4	NULL
,	NULL
329-339	NULL
.	NULL

Crabtree	NULL
,	NULL
G.R	NULL
.	NULL

and	NULL
Clipstone	NULL
,	NULL
N.A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Biochem	NULL
.	NULL

,	NULL
63	NULL
,	NULL
1045-1083	NULL
.	NULL

Crawley	NULL
,	NULL
G.C	NULL
.	NULL

et	NULL
al	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
J.	NULL
Lipid	NULL
Mediat	NULL
.	NULL

,	NULL
6	NULL
,	NULL
249-257	NULL
.	NULL

Ford-Hutchinson	NULL
,	NULL
A.W	NULL
.	NULL

,	NULL
Gresser	NULL
,	NULL
M	NULL
.	NULL

and	NULL
Young	NULL
,	NULL
R.N	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Biochem	NULL
.	NULL

,	NULL
63	NULL
,	NULL
383-417	NULL
.	NULL

Frantz	NULL
,	NULL
B.	NULL
,	NULL
Nordby	NULL
,	NULL
E.C	NULL
.	NULL

,	NULL
Bren	NULL
,	NULL
G.	NULL
,	NULL
Steffan	NULL
,	NULL
N.	NULL
,	NULL
Paya	NULL
,	NULL
C.V.	NULL
,	NULL
Kincaid	NULL
,	NULL
R.L	NULL
.	NULL

,	NULL
Tocci	NULL
,	NULL
M.J.	NULL
,	NULL
O'Keefe	NULL
,	NULL
S.J	NULL
.	NULL

and	NULL
O'Neill	NULL
,	NULL
E.A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
EMBO	NULL
J.	NULL
,	NULL
13	NULL
,	NULL
861-870	NULL
.	NULL

Fraser	NULL
,	NULL
J.D	NULL
.	NULL

,	NULL
Irving	NULL
,	NULL
B.A	NULL
.	NULL

,	NULL
Crabtree	NULL
,	NULL
G.R	NULL
.	NULL

and	NULL
Weiss	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Science	NULL
,	NULL
251	NULL
,	NULL
313-316	NULL
.	NULL

Gagnon	NULL
,	NULL
L.	NULL
,	NULL
Filion	NULL
,	NULL
L.G	NULL
.	NULL

,	NULL
Dubois	NULL
,	NULL
C	NULL
.	NULL

and	NULL
Rola-Pleszezynski	NULL
,	NULL
M	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Agents	NULL
Actions	NULL
,	NULL
26	NULL
,	NULL
141-147	NULL
.	NULL

Ghosh	NULL
,	NULL
P.	NULL
,	NULL
Tan	NULL
,	NULL
T.-H.	NULL
,	NULL
Rice	NULL
,	NULL
N.R	NULL
.	NULL

,	NULL
Sica	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Young	NULL
,	NULL
H.A	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

,	NULL
90	NULL
,	NULL
1696-1700	NULL
.	NULL

Guba	NULL
,	NULL
S.C.	NULL
,	NULL
Stella	NULL
,	NULL
G.	NULL
,	NULL
Turka	NULL
,	NULL
L.A.	NULL
,	NULL
June	NULL
,	NULL
.C.H	NULL
.	NULL

,	NULL
Thompson	NULL
,	NULL
C.B	NULL
.	NULL

and	NULL
Emerson	NULL
,	NULL
$	NULL
.G	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

,	NULL
84	NULL
,	NULL
1701-1706	NULL
.	NULL

Halliwell	NULL
,	NULL
B	NULL
.	NULL

and	NULL
Gutteridge	NULL
,	NULL
J.M.C	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Methods	NULL
Enzymol	NULL
.	NULL

,	NULL
186	NULL
,	NULL
1-85	NULL
.	NULL

Harding	NULL
,	NULL
FA	NULL
.	NULL

,	NULL
Mc	NULL
Arthur	NULL
,	NULL
J.G	NULL
.	NULL

,	NULL
Gross	NULL
,	NULL
J.A	NULL
.	NULL

,	NULL
Raulet	NULL
,	NULL
D.H	NULL
.	NULL

and	NULL
Allison	NULL
,	NULL
J.P	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Nature	NULL
,	NULL
356	NULL
,	NULL
607-609	NULL
.	NULL

Hutchcroft	NULL
,	NULL
JE	NULL
.	NULL

and	NULL
Bierer	NULL
,	NULL
B.E	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
91	NULL
,	NULL
3260-3264	NULL
.	NULL

Izquierdo	NULL
Pastor	NULL
,	NULL
M.	NULL
,	NULL
Reif	NULL
,	NULL
K.	NULL
and	NULL
Cantrell	NULL
,	NULL
D	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Immunol	NULL
.	NULL

Today	NULL
,	NULL
16	NULL
,	NULL
159-164	NULL
.	NULL

Jenkins	NULL
,	NULL
and	NULL
Johnson	NULL
,	NULL
J.G	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Curr	NULL
Opinion	NULL
Immunol	NULL
.	NULL

,	NULL
5	NULL
,	NULL
361-367	NULL
.	NULL

Jonat	NULL
,	NULL
C.	NULL
,	NULL
Rahmsdorf	NULL
,	NULL
H.J	NULL
.	NULL

,	NULL
Park	NULL
,	NULL
K.K	NULL
.	NULL

,	NULL
Cato	NULL
,	NULL
Gebel	NULL
,	NULL
S.	NULL
,	NULL
Ponta	NULL
,	NULL
H	NULL
.	NULL

and	NULL
Herrlich	NULL
,	NULL
P	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Cell	NULL
,	NULL
62	NULL
,	NULL
1205-1215	NULL
.	NULL

June	NULL
,	NULL
C.H	NULL
.	NULL

,	NULL
Ledbetter	NULL
,	NULL
J.A	NULL
.	NULL

,	NULL
Gillespie	NULL
,	NULL
Lindsten	NULL
,	NULL
T	NULL
.	NULL

and	NULL
Thompson	NULL
,	NULL
C.B	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
7	NULL
,	NULL
4472-4481	NULL
.	NULL

June	NULL
,	NULL
C.H	NULL
.	NULL

,	NULL
Ledbetter	NULL
,	NULL
J.A	NULL
.	NULL

,	NULL
Linsley	NULL
,	NULL
PS	NULL
.	NULL

and	NULL
Thompson	NULL
,	NULL
C.B	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Immunol	NULL
.	NULL

Today	NULL
,	NULL
11	NULL
,	NULL
211-216	NULL
.	NULL

June	NULL
,	NULL
C.H	NULL
.	NULL

,	NULL
Bluestone	NULL
,	NULL
J.A	NULL
.	NULL

,	NULL
Nadler	NULL
,	NULL
LM	NULL
.	NULL

and	NULL
Thompson	NULL
,	NULL
C.B	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Immunol	NULL
.	NULL

Today	NULL
,	NULL
15	NULL
,	NULL
321-331	NULL
.	NULL

Ledbetter	NULL
,	NULL
J.A	NULL
.	NULL

,	NULL
Parsons	NULL
,	NULL
M.	NULL
,	NULL
Martin	NULL
,	NULL
PJ	NULL
.	NULL

,	NULL
Hansen	NULL
,	NULL
J.A	NULL
.	NULL

,	NULL
Rabinovitch	NULL
,	NULL
P.S	NULL
.	NULL

and	NULL
June	NULL
,	NULL
C.H	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
137	NULL
,	NULL
3299-3305	NULL
.	NULL

Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Imboden	NULL
,	NULL
J.B.	NULL
,	NULL
Schieven	NULL
,	NULL
G.L	NULL
.	NULL

,	NULL
Grosmaire	NULL
,	NULL
L.S	NULL
.	NULL

,	NULL
Rabinovitch	NULL
,	NULL
P.S	NULL
.	NULL

,	NULL
Lindsten	NULL
,	NULL
T.	NULL
,	NULL
Thompson	NULL
,	NULL
C.B	NULL
.	NULL

and	NULL
June	NULL
,	NULL
C.H	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Blood	NULL
,	NULL
75	NULL
,	NULL
1531-1539	NULL
.	NULL

Lister	NULL
,	NULL
M.D	NULL
.	NULL

,	NULL
Glaser	NULL
,	NULL
K.B	NULL
.	NULL

,	NULL
Ulevitch	NULL
,	NULL
R.J	NULL
.	NULL

and	NULL
Dennis	NULL
,	NULL
E.A	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
264	NULL
,	NULL
8520-8528.	NULL
van	NULL
Lier	NULL
,	NULL
R.A.W	NULL
.	NULL

,	NULL
Brouwer	NULL
,	NULL
M.	NULL
,	NULL
De	NULL
Groot	NULL
,	NULL
E.	NULL
,	NULL
Kramer	NULL
,	NULL
I.	NULL
,	NULL
Aarden	NULL
,	NULL
L.A	NULL
.	NULL

and	NULL
Verhoeven	NULL
,	NULL
A.J	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Eur	NULL
.	NULL

J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
21	NULL
,	NULL
1775-1778	NULL
.	NULL

Lindsten	NULL
,	NULL
T.	NULL
,	NULL
June	NULL
,	NULL
C.H	NULL
.	NULL

,	NULL
Ledbetter	NULL
,	NULL
J.A	NULL
.	NULL

,	NULL
Stella	NULL
,	NULL
G	NULL
.	NULL

and	NULL
Thompson	NULL
,	NULL
C.B	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Science	NULL
,	NULL
244	NULL
,	NULL
339-343	NULL
.	NULL

Linsley	NULL
,	NULL
P.S	NULL
.	NULL

and	NULL
Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
11	NULL
,	NULL
191-212	NULL
.	NULL

Linsley	NULL
,	NULL
PS	NULL
.	NULL

,	NULL
Brady	NULL
,	NULL
W.	NULL
,	NULL
Urnes	NULL
,	NULL
M.	NULL
,	NULL
Grosmaire	NULL
,	NULL
L.S	NULL
.	NULL

,	NULL
Damle	NULL
,	NULL
N.K	NULL
.	NULL

and	NULL
Ledbetter	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
174	NULL
,	NULL
561-569	NULL
.	NULL

Los	NULL
,	NULL
M.	NULL
,	NULL
Drége	NULL
,	NULL
W	NULL
.	NULL

and	NULL
Schulze-Osthoff	NULL
,	NULL
K	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Biochem	NULL
.	NULL

J.	NULL
,	NULL
302	NULL
,	NULL
119-123	NULL
.	NULL

Lu	NULL
,	NULL
Y.	NULL
,	NULL
Granelli-Piperno	NULL
,	NULL
A.	NULL
,	NULL
Bjorndahl	NULL
,	NULL
J.M	NULL
.	NULL

,	NULL
Phillips	NULL
,	NULL
C.A	NULL
.	NULL

and	NULL
Trevillyan	NULL
,	NULL
J.M	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
J	NULL
.	NULL

/mmunol	NULL
.	NULL

,	NULL
149	NULL
,	NULL
24-29	NULL
.	NULL

Lu	NULL
,	NULL
¥Y	NULL
.	NULL

,	NULL
Phillips	NULL
,	NULL
C	NULL
.	NULL

and	NULL
Trevillyan	NULL
,	NULL
J.M	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Eur	NULL
J	NULL
.	NULL

immunol	NULL
.	NULL

,	NULL
25	NULL
,	NULL
533-537	NULL
.	NULL

Martin	NULL
,	NULL
PJ	NULL
.	NULL

,	NULL
Ledbetter	NULL
,	NULL
J.A	NULL
.	NULL

,	NULL
Morishita	NULL
,	NULL
Y.	NULL
,	NULL
June	NULL
,	NULL
C.H	NULL
.	NULL

,	NULL
Beatty.1G	NULL
.	NULL

and	NULL
Hansen	NULL
,	NULL
J.A	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
J	NULL
.	NULL

/mmunol	NULL
.	NULL

,	NULL
136	NULL
,	NULL
3282-3287	NULL
.	NULL

Meyer	NULL
,	NULL
M.	NULL
,	NULL
Schreck	NULL
,	NULL
R	NULL
.	NULL

and	NULL
Bacuerle	NULL
,	NULL
P.A	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
EMBO	NULL
J.	NULL
,	NULL
12	NULL
,	NULL
2005	NULL
2015	NULL
.	NULL

Mihm	NULL
,	NULL
S.	NULL
,	NULL
Ennen	NULL
,	NULL
J.	NULL
,	NULL
Pessara	NULL
,	NULL
U.	NULL
,	NULL
Kurth.R	NULL
.	NULL

and	NULL
Dréoge	NULL
,	NULL
W	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
AZDS	NULL
,	NULL
5	NULL
,	NULL
497-503	NULL
.	NULL

Mueller	NULL
,	NULL
D.L	NULL
.	NULL

,	NULL
Jenkins	NULL
,	NULL
M.K	NULL
.	NULL

and	NULL
Schwartz	NULL
,	NULL
R.H	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
7	NULL
,	NULL
445-480	NULL
.	NULL

Nunés	NULL
,	NULL
J.	NULL
,	NULL
Klasen	NULL
,	NULL
$	NULL
.	NULL

,	NULL
Franco	NULL
,	NULL
M.-D.	NULL
,	NULL
Lipcey	NULL
,	NULL
C.	NULL
,	NULL
Mawas	NULL
,	NULL
C.	NULL
,	NULL
Bagnasco	NULL
,	NULL
M	NULL
.	NULL

and	NULL
Olive	NULL
,	NULL
D	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Biochem	NULL
.	NULL

J.	NULL
,	NULL
293	NULL
,	NULL
835-842	NULL
.	NULL

Nunés	NULL
,	NULL
J.A	NULL
.	NULL

,	NULL
Colette	NULL
,	NULL
Y.	NULL
,	NULL
Truneh	NULL
,	NULL
A.	NULL
,	NULL
Olive	NULL
,	NULL
D.	NULL
and	NULL
Cantrell	NULL
,	NULL
D.A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
180	NULL
,	NULL
1067-1076	NULL
.	NULL

Pages	NULL
,	NULL
F.	NULL
,	NULL
Ragueneau	NULL
,	NULL
M.	NULL
,	NULL
Rottapel	NULL
,	NULL
R.	NULL
,	NULL
Truneh	NULL
,	NULL
A.	NULL
,	NULL
Nunes.J	NULL
.	NULL

,	NULL
imbert	NULL
,	NULL
J	NULL
.	NULL

and	NULL
Olive	NULL
,	NULL
D	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Nature	NULL
,	NULL
369	NULL
,	NULL
327-329	NULL
.	NULL

Paliogianni	NULL
,	NULL
F.	NULL
,	NULL
Raptis	NULL
,	NULL
A.	NULL
,	NULL
Ahuyja	NULL
,	NULL
$	NULL
.S	NULL
.	NULL

,	NULL
Najjar	NULL
,	NULL
S.M	NULL
.	NULL

,	NULL
Boumpas	NULL
,	NULL
D.T	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

,	NULL
91	NULL
,	NULL
1481-1489	NULL
.	NULL

Prasad	NULL
,	NULL
Cai	NULL
,	NULL
Y.-C.	NULL
,	NULL
Raab	NULL
,	NULL
M.	NULL
,	NULL
Duckworth	NULL
,	NULL
B.	NULL
,	NULL
Cantley	NULL
,	NULL
L.	NULL
,	NULL
Shoelson	NULL
,	NULL
S.E	NULL
.	NULL

and	NULL
Rudd	NULL
,	NULL
C	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Proc	NULL
.	NULL

Nat	NULL
!	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
91	NULL
,	NULL
2834-2838	NULL
.	NULL

Punt	NULL
,	NULL
J.A	NULL
.	NULL

,	NULL
Osborne	NULL
,	NULL
B.A	NULL
.	NULL

,	NULL
Takahama	NULL
,	NULL
J.	NULL
,	NULL
Sharrow	NULL
,	NULL
S.0	NULL
.	NULL

and	NULL
Singer	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
179	NULL
,	NULL
709-713	NULL
.	NULL

Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Immunol	NULL
.	NULL

Today	NULL
,	NULL
15	NULL
,	NULL
274-281	NULL
.	NULL

3740	NULL
Rice	NULL
,	NULL
G.C	NULL
.	NULL

,	NULL
Bump	NULL
,	NULL
E.A	NULL
.	NULL

,	NULL
Shrieve	NULL
,	NULL
D.C.	NULL
,	NULL
Lee	NULL
,	NULL
W	NULL
.	NULL

and	NULL
Kovacs	NULL
,	NULL
M	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
Cancer	NULL
Res	NULL
.	NULL

,	NULL
46	NULL
,	NULL
6105-6510	NULL
.	NULL

Rincon	NULL
,	NULL
M	NULL
.	NULL

and	NULL
Flavell	NULL
,	NULL
R.A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
EMBO	NULL
J.	NULL
,	NULL
13	NULL
,	NULL
4370-4381	NULL
.	NULL

Rola-Pleszcezynski	NULL
,	NULL
M	NULL
.	NULL

and	NULL
Stankova	NULL
,	NULL
M	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Blood	NULL
,	NULL
80	NULL
,	NULL
1004-1011	NULL
.	NULL

Rola-Pleszczynski	NULL
,	NULL
M.	NULL
,	NULL
Thivierge.M	NULL
.	NULL

,	NULL
Gagnon	NULL
,	NULL
N.	NULL
,	NULL
Lacasse	NULL
,	NULL
C	NULL
.	NULL

and	NULL
StankovaJ	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
J.	NULL
Lipid	NULL
Mediat	NULL
.	NULL

,	NULL
6	NULL
,	NULL
175-181	NULL
.	NULL

Rouzer	NULL
,	NULL
C.A	NULL
.	NULL

,	NULL
Ford-Hutchinson	NULL
,	NULL
A.W	NULL
.	NULL

,	NULL
Morton	NULL
,	NULL
H.E	NULL
.	NULL

and	NULL
Gillard	NULL
,	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
265	NULL
,	NULL
1436-1442	NULL
.	NULL

Royall	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
and	NULL
Ischiropoulus	NULL
,	NULL
H	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Arch	NULL
.	NULL

Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

,	NULL
302	NULL
,	NULL
348-355	NULL
.	NULL

Samuelsson	NULL
,	NULL
B.	NULL
,	NULL
Dahlén	NULL
,	NULL
$	NULL
.-E.	NULL
,	NULL
Lindgren	NULL
,	NULL
J.A	NULL
.	NULL

,	NULL
Rouzer	NULL
,	NULL
C.A	NULL
.	NULL

and	NULL
Sherhan	NULL
,	NULL
C.A	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Science	NULL
,	NULL
237	NULL
,	NULL
1171-1176	NULL
.	NULL

Schenk	NULL
,	NULL
H.	NULL
,	NULL
Klein	NULL
,	NULL
M.	NULL
,	NULL
Erdbriigger	NULL
,	NULL
W.	NULL
,	NULL
Dréoge	NULL
,	NULL
W.	NULL
and	NULL
Schulze-Osthoff	NULL
,	NULL
K	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
91	NULL
,	NULL
1672-1676	NULL
.	NULL

Schreck	NULL
,	NULL
R.	NULL
,	NULL
Rieber	NULL
,	NULL
P	NULL
.	NULL

and	NULL
Bacuerle	NULL
,	NULL
P.A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
EMBO	NULL
J.	NULL
,	NULL
10	NULL
,	NULL
2247-2258	NULL
.	NULL

Schulze-Osthoff	NULL
,	NULL
K	NULL
.	NULL

and	NULL
Baecuerle	NULL
,	NULL
PA	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Adv	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

,	NULL
in	NULL
press	NULL
.	NULL

Schulze-Osthoff	NULL
,	NULL
K.	NULL
,	NULL
Beyaert	NULL
,	NULL
R.	NULL
,	NULL
Vandevoorde	NULL
,	NULL
V.	NULL
,	NULL
Haegeman.G	NULL
.	NULL

and	NULL
Fiers	NULL
,	NULL
W.	NULL
(	NULL
1993	NULL
)	NULL
EMBO	NULL
J.	NULL
,	NULL
12	NULL
,	NULL
3095-3104	NULL
.	NULL

Staal	NULL
,	NULL
FJ.T	NULL
.	NULL

,	NULL
Roederer	NULL
,	NULL
M.	NULL
,	NULL
Herzenberg	NULL
,	NULL
L.A	NULL
.	NULL

and	NULL
Herzenberg	NULL
,	NULL
L.A	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
87	NULL
,	NULL
9943-9947	NULL
.	NULL

Stankova	NULL
,	NULL
J.	NULL
,	NULL
Dupuis	NULL
,	NULL
G.	NULL
,	NULL
Gagnon	NULL
,	NULL
N.	NULL
,	NULL
Thivierge	NULL
,	NULL
M.	NULL
,	NULL
Turcotte	NULL
,	NULL
S	NULL
.	NULL

and	NULL
Rola-Pleszezynski	NULL
,	NULL
M	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
150	NULL
,	NULL
4041-4051	NULL
.	NULL

S	NULL
$	NULL
u	NULL
,	NULL
B.	NULL
,	NULL
Jacinto	NULL
,	NULL
E.	NULL
,	NULL
Hibi	NULL
,	NULL
M.	NULL
,	NULL
Kallunki	NULL
,	NULL
T.	NULL
,	NULL
Karin	NULL
,	NULL
M	NULL
.	NULL

and	NULL
Ben-Neriah	NULL
,	NULL
Y	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Cell	NULL
,	NULL
77	NULL
,	NULL
727-736	NULL
.	NULL

Thompson	NULL
,	NULL
C.B	NULL
.	NULL

,	NULL
Lindsten	NULL
,	NULL
T.	NULL
,	NULL
LedbetterJ.A	NULL
.	NULL

,	NULL
Kunkel	NULL
,	NULL
S.L	NULL
.	NULL

,	NULL
Young	NULL
,	NULL
H.A	NULL
.	NULL

,	NULL
Emerson	NULL
,	NULL
$	NULL
.G	NULL
.	NULL

,	NULL
Leiden	NULL
,	NULL
J.M	NULL
.	NULL

and	NULL
June	NULL
,	NULL
C.H	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
Acad	NULL
.	NULL

Sei	NULL
.	NULL

USA	NULL
,	NULL
86	NULL
,	NULL
1333-1337	NULL
.	NULL

Truitt	NULL
,	NULL
C.E	NULL
.	NULL

,	NULL
Hicks	NULL
,	NULL
C.M	NULL
.	NULL

and	NULL
Imboden	NULL
,	NULL
J.B	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
179	NULL
,	NULL
1071-1076	NULL
.	NULL

Uehara	NULL
,	NULL
Y	NULL
.	NULL

and	NULL
Fukazawa	NULL
,	NULL
H	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Methods	NULL
Enzymol	NULL
.	NULL

,	NULL
201	NULL
,	NULL
370-378	NULL
.	NULL

Vacca	NULL
,	NULL
A.	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
175	NULL
,	NULL
637-646	NULL
.	NULL

Vandenberghe	NULL
,	NULL
P.	NULL
,	NULL
Freeman	NULL
,	NULL
G.J	NULL
.	NULL

,	NULL
Nadler	NULL
,	NULL
L.M	NULL
.	NULL

,	NULL
Fletcher	NULL
,	NULL
M.C	NULL
.	NULL

,	NULL
Kamoun	NULL
,	NULL
M.	NULL
,	NULL
Turka	NULL
,	NULL
L.A.	NULL
,	NULL
Ledbetter	NULL
-	NULL
Thompson	NULL
,	NULL
C.B	NULL
.	NULL

and	NULL
June	NULL
,	NULL
C.H	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

,	NULL
175	NULL
,	NULL
951-960	NULL
.	NULL

Verweij	NULL
,	NULL
C.L	NULL
.	NULL

,	NULL
Geerts	NULL
,	NULL
M	NULL
.	NULL

and	NULL
Aarden	NULL
,	NULL
L.A	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
266	NULL
,	NULL
14179-14182	NULL
.	NULL

Weiss	NULL
,	NULL
A.	NULL
and	NULL
Littman	NULL
,	NULL
D.R	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Cell	NULL
,	NULL
76	NULL
,	NULL
263-274	NULL
.	NULL

Received	NULL
on	NULL
December	NULL
2	NULL
,	NULL
1994	NULL
;	NULL
revised	NULL
on	NULL
April	NULL
10	NULL
,	NULL
1995	NULL

